Protocol J2T -MC-KGBO(a)
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupi[INVESTIGATOR_12458]
[STUDY_ID_REMOVED]   
Approval Date: 27-Apr-202 3 
CONFIDENTIAL  J2T-MC-KGBO (a) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_81157] (LY3650150 ), unless  such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commerci ally confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and 
Adolescent Participants  with Moderate -to-Severe Atopic Dermatitis Previously Treated with 
Dupi[INVESTIGATOR_81158]:  J2T-MC-KGBO  
Amendment Number:  a  
Compound : lebrikizumab (LY3650150 ) 
Brief Title:  
A Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants  with Moderate -to-Severe Atopic Dermatitis Previously Treated with Dupi[INVESTIGATOR_81159]:  3b 
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number : 
IND: 119866  
Document ID:  VV-CLIN -093432  
Approval Date:  Protocol Amendmen t (a) Electronically  Signed and  Approved  by [CONTACT_10937] .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88437] Information will be provided separately . 
 
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
3 Protocol Amendment Summary of Changes Table   
DOCUMENT HISTORY  
Document  Date  
Original Protocol  16-Aug-2022  
Amendment [a]  
This amendment is considered to be substantial.  
The amendment is considered to be substantial because it is likely to have a significant impact on 
the interpretation of the data generated in the clinical study.  
Overall Rationale for the Amendment:  
The main rationale for this  amendment is provided below  
Section # and Name  [CONTACT_11029]  
1.1. Synopsis and  
3. Objectives, Endpoints, 
and Estimands  Revised the primary 
clinical research question 
and the attributes of the 
primary estimand.  To ensure that the primary clinical 
research question, primary estimand, 
and primary analysis are in alignment.  
The original treatment policy 
estimand is not aligned with the as -
observed analysis  
6.6. Continued Access to 
Study Intervention after 
the End of the Study  Updated to allow 
continued access to 
lebrikizumab for eligible 
participants who 
complete Visit 9 (Week 
24) Provide an uninterrupted supply of 
lebrikizumab to qualified participants, 
via the Continued Access addendum, 
until lebrikizumab is comm ercially 
available in the US  
6.8.1 Permitted 
Treatments and 
Procedures  Added use of high -
potency TCS up to  10 
days Permitting high -potency TCS for up to 
10 days is similar to the real -world 
setting  
6.8.2 Prohibited 
Treatments and 
Procedures  Updated  use of high-
potency TCS  for >[ADDRESS_88438] ‘may’  The intent is to convey that the use of 
emollients is not mandatory, but 
recommended  
6.8.4 Topi[INVESTIGATOR_81160] -
potency TCS >10 days  Permitting high -potency TCS > 10 
days will be considered as rescue 
medication  6.8.5 Rescue treatment  
for Atopic Dermatitis  Added use of high -
potency TCS >10 days 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
4 Section # and Name  [CONTACT_11029]  
9.2. Analyses Sets  Added “population” to 
describe ITT and Safety 
analysis set  Clarification  
9.3.2. Primary 
Endpoint(s)/Estimand(s) 
Analysis  Revised the primary 
clinical question of 
interest  To align primary estimand with 
primary analysis. The original 
treatment policy estimand is not 
aligned with the as -observed analysis   
9.3.3.  Secondary 
Endpoint(s)/Estimand(s) 
Analysis  Removed reference to the 
treatment policy strategy 
for secondary endpoints  To clarify that secondary endpoints 
will be analy zed similarly to the 
primary endpoint of the primary 
estimand, that is,  using all observed 
data. The original treatment policy 
estimand is not aligned with the as -
observed analysis  
9.3.4.  Exploratory 
Endpoint(s) Analysis  Removed reference to the 
treatment  policy strategy 
for exploratory endpoints  To clarify that exploratory endpoints 
will be analyzed similarly to the 
primary endpoint of the primary 
estimand, that is,  using all observed 
data. The original treatment policy 
estimand is not aligned with the as -
observed analysis  
10.3.6. Regulatory 
Reporting Requirements  
SAE Regulatory 
Reporting  Added text for suspected 
unexpected serious 
adverse reactions  Alignment with latest  guidance  
Throughout  Minor editorial changes 
have been made 
throughout  These are minor, therefore they have 
not been individually summarized  
 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
5 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 9 
1.1. Synopsis  ................................ ................................ ................................ ............................ 9 
1.2. Schema  ................................ ................................ ................................ ............................ 14 
1.3. Schedule of  Activities (SoA)  ................................ ................................ .......................... 15 
2. Introduction  ................................ ................................ ................................ ................... 25 
2.1. Study Rationale  ................................ ................................ ................................ ............... 25 
2.2. Background  ................................ ................................ ................................ ..................... 26 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 29 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......30 
4. Study Design  ................................ ................................ ................................ .................. 34 
4.1. Overall  Design  ................................ ................................ ................................ ................ 34 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 34 
4.2.1.  Participant Input into Design  ................................ ................................ .......................... 35 
4.3. Justification for Dose  ................................ ................................ ................................ ......35 
4.4. End of Study Definition  ................................ ................................ ................................ ..35 
5. Study Population  ................................ ................................ ................................ ........... 37 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 37 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 38 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .41 
5.4. Screen Failures  ................................ ................................ ................................ ................ 41 
5.4.1.  Rescreening for Individuals Who Failed Screening  ................................ ....................... 41 
5.5. Criteria for Temporarily Delaying Enrollment/Administration of 
Study Inte rvention of a Participant  ................................ ................................ ................. 41 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 42 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 42 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 42 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 42 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 43 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 43 
6.5. Dose Modification  ................................ ................................ ................................ .......... 43 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 43 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...44 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....44 
6.8.1.  Permitted Treatments and Procedures  ................................ ................................ ............ 44 
6.8.2.  Prohibited Treatments and Procedures  ................................ ................................ ........... 45 
6.8.3.  Non-Medicated Moisturizers  ................................ ................................ .......................... 46 
6.8.4.  Topi[INVESTIGATOR_81161]  ................................ ................................ .......46 
6.8.5.  Rescue Medicine for Atopic Dermatitis  ................................ ................................ ......... 47 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 48 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 48 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
6 7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................. 49 
7.1.2.  Temporary Discontinuation of Study Intervention  ................................ ......................... 49 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_88439] to Follow -up................................ ................................ ................................ ............ 51 
8. Study Assessments and Procedures ................................ ................................ ............. 52 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....52 
8.1.1.  Eczema Area and Severity Index  ................................ ................................ .................... 52 
8.1.2.  Investigator’s Global Assessment (IGA)  ................................ ................................ ........ 52 
8.1.3.  Body Surface Area ( BSA)  ................................ ................................ .............................. 53 
8.1.4.  Face -Investigator’s Global Assessment (F -IGA) ................................ ............................ 53 
8.1.5.  SCORing Atopic Dermatitis (SCORAD)  ................................ ................................ .......53 
8.1.6.  Modified Total Lesion Symptom Scale  ................................ ................................ .......... 53 
8.1.7.  Pruritus NRS  ................................ ................................ ................................ ................... 54 
8.1.8.  Sleep -Loss Scale  ................................ ................................ ................................ ............. 54 
8.1.9.  Skin Pain Numeric Rating Scale (Skin Pain NRS)  ................................ ......................... 54 
8.1.10.  Dermatology Life Quality Index/Children’s Dermatology Life 
Quality Index (DLQI/cDLQI)  ................................ ................................ ......................... 54 
8.1.11 . Atopic Dermatitis Control Tool (ADCT)  ................................ ................................ .......55 
8.1.12.  Participant -Reported Satisfaction Question  ................................ ................................ ....55 
8.1.13.  Fitzpatrick Skin Phototype Assessment  ................................ ................................ .......... 55 
8.1.14.  Work Productivity and Activity Impairment Questionnaire –
Atopic Dermatitis (WPAI -AD) ................................ ................................ ....................... [ADDRESS_88440]  ................................ ................................ ................. 64 
8.3.4.  Facial Dermatitis  ................................ ................................ ................................ ............. 64 
8.3.5.  Hypersensitivity  ................................ ................................ ................................ .............. 64 
8.3.6.  Injection Site Reactions  ................................ ................................ ................................ ..64 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 64 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 65 
8.6. Genetics  ................................ ................................ ................................ .......................... 65 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 65 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 65 
8.9. Health Economics  ................................ ................................ ................................ ........... 66 
9. Statistical Considerations  ................................ ................................ ............................. 67 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....67 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 67 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 67 
9.3.1.  General Considerations  ................................ ................................ ................................ ...67 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
7 9.3.2.  Primary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ ....67 
9.3.3.  Secondary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ 68 
9.3.4.  Exploratory Endpoint(s) Analysis ................................ ................................ ................... 68 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 68 
9.3.6.  Other Analyses  ................................ ................................ ................................ ................ 68 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 69 
9.5. Sample Size Determination  ................................ ................................ ............................ 69 
10. Supporting Documentation and Operational Considerations  ................................ ..71 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 71 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 71 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 71 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 72 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 72 
10.1.5. Dissemination of Clinical Study Data ................................ ................................ ............. 73 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..73 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 75 
10.1.8.  Study and Site Start  and Closure  ................................ ................................ .................... 75 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 76 
10.1.10.  Investigator Information  ................................ ................................ ................................ .76 
10.1.11.  Sample Retention  ................................ ................................ ................................ ............ 76 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 77 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event  ................................ ................................ ................................ ....79 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ [ADDRESS_88441] Complaints  ................................ ................................ ................... 83 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 84 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 86 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 86 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 87 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 87 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..87 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......89 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 90 
10.7.  Appendix 7: American Academy of Dermatology: Criteria for 
the Diagnosis and Assessment of Atopic Dermatitis  ................................ ...................... 92 
10.8.  Appendix 8: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ............ 93 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
8 10.9.  Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy  ................................ ........................... 94 
10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 96 
10.11.  Appendix 11: Abbreviations and Definitions  ................................ ................................ .98 
11. References  ................................ ................................ ................................ .................... 102 
 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
9 1. Protocol Summary   
1.1. Synopsis   
Protocol Title:   
An Open -Label Study to Evaluate the Safety and Efficacy of Lebrikizumab i n Adult and 
Adolescent Participants  with Moderate -to-Severe Atopic Dermatitis Previously Treated with 
Dupi[INVESTIGATOR_81162]:   
A Study to Evaluate  the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants  with Moderate -to-Severe Atopic Dermatitis Previously Treated with Dupi[INVESTIGATOR_81163] : 
Atopic dermatitis (AD) is a chronic heterogeneous inflammatory skin disorder c aused by [CONTACT_81236]. Due to the heterog eneous nature 
of the disease , patients have diverse treatment  needs.  Standard treatment modalities for the 
management of these patients are centered around the us e of topi[INVESTIGATOR_900] -inflammatory 
preparations and skin moisturizers , but patients with moderate -to-sever e disease may require 
phototherapy or systemic treatment . Dupi[INVESTIGATOR_12458], a monoclonal antibody which inhibits  the 
signaling of interleukin  (IL)-[ADDRESS_88442] or loss of access  (for example, insurance ) to the drug.  Taken 
together, a significant number of patients  do not continue dupi[INVESTIGATOR_81164].  In the pi[INVESTIGATOR_81165] 3 trials, 36 % to 38% of 
participants achieved the primary endpoint of an Investigator Global Assessment ( IGA) (0,1) 
with a ≥2 -point reduction in IGA and 44 % to 51% achieved Eczema Area and Severity Index -75 
(EASI -75) data from baseline to Week 16, indicating that a significant  proportion of the patients 
did not achieve clinical response. (Simpson et al. 2016).  
Therefore, there is an important gap in the clinical care of these patients for whom novel 
therapi[INVESTIGATOR_81166] . 
In patients with A D, IL -13, a central pathogenic mediator in the disease, is overexpressed, 
driving multiple aspects of AD pathophysiology by [CONTACT_6561] T-helper type 2 (Th2)  cell 
inflammation and resulting in skin barrier dysfunction, itch, infection , and lichenification.  
Dupi[INVESTIGATOR_24783] a monoclonal antibody that binds to the shared α subunit of the IL-4 and IL-13 
receptors, thereby [CONTACT_81237]-4 and IL-13. IL -4 is the driver of the 
differentiation of naïve CD4+ T cells into Th2 cells and a negative regulat or of Th1 and Th17 
pathways. Blockade of Th2 differentiation by [CONTACT_24983][INVESTIGATOR_81167] a dysregulation in the 
T-helper balance, providing a mechanistic explanation for the development of Th1/Th17 diseases 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
10 in dupi[INVESTIGATOR_12458] -treated patients ( Tracey et al. 2018; Safa and Paumier 2019; Varma and Levitt 
2020 ; Heibel et al. 2021).  
IL-13 is considered a key cytokine in AD (Tsoi et al. 2019 and reviewed in Bieber  et al.  2020).  
Lebrikizumab specifically blocks IL -13 and therefore also IL -13 signaling via the IL-4 recept or 
alpha ( IL-4R)/IL-13 receptor alpha 1 ( IL-13R1) heterodimer complex. Important differences 
between dupi[INVESTIGATOR_81168], respectively, and 
known strong binding affinity and lack of effect on IL -[ADDRESS_88443] when bound to lebrikizumab, because 
lebrikizumab does not inhibit the binding of IL -13 to the decoy receptor, IL -13Rα2. 
Lebrikizumab  phase 2 and  3 data demonstrated its efficacy in AD. Leveraging data from both 
phase 2b monotherapy and phase 3 topi[INVESTIGATOR_33424]  (TCS) combination therapy in which 
dupi[INVESTIGATOR_81169], lebrikizumab showed consistent treatment effects 
in both dupi[INVESTIGATOR_81170]ïve and dupi[INVESTIGATOR_12458] e xperienced participants. Nevertheless, those trials were 
not designed to evaluate this specific patient population.  
This trial aims to specifically evaluate the safety and efficacy of lebrikizumab in patients 
previous ly treated with dupi[INVESTIGATOR_12458].  
Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary   
 To evaluate efficacy of 
lebrikizumab 250 mg Q2W 
on reducing signs and 
symptoms of AD at Week 
16 in participants with 
moderate -to-severe AD 
previous ly treated with  
dupi[INVESTIGATOR_12458]   Percentage of participants achieving EASI -75 
at Week 16  
Secondary   
 To evaluate the efficacy of 
lebrikizumab on reducing 
signs and symptoms of AD 
at Week 16 and Week 24 in 
participants with 
moderate -to-severe AD  
previous ly treated with  
dupi[INVESTIGATOR_12458]   Percentage of participants achieving EASI -75 
at Week 24  
 Percentage of participants with an IGA score 
of 0 or 1 and a reduction ≥2 points from 
baseline to Week s 16 and 24   
 Percentage change in EASI from baseline to 
Week s 16 and 24  
 Change in EASI from baseline to Week s 16 
and 24  
 Percentage of participant s achieving EASI -90 
from baseline to Week s 16 and 24  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
11  Percentage of participants with a Pruritus 
NRS of ≥[ADDRESS_88444] 4 -point reduction at Week s 16 and 24  
 Percentage of participants with a Pruritus 
NRS ≥ [ADDRESS_88445] 3 -point reduction  at Week s 16 and 24  
 Percentage change in Pruritus NRS score from 
baseline to Week s 16 and 24  
 Percentage of participants with a Sleep -Loss 
Scale of ≥[ADDRESS_88446] 2 -point reduction at Week s 16 and 24  
 Change in Sleep -Loss Scale from baseline at 
Week s 16 and 24  
 Percentage of participants  with a Skin Pain 
NRS of ≥4  points at baseline who achieve a 
4-point reduction from baseline at Week s 16 
and 24   
 Change in Skin Pain NRS from baseline to 
Week s 16 and 24   
 Change in DLQI from baseline to Week s 16 
and Week 24 for participants ≥16 years of age 
at baseline  
 Percentage of participants with at least 4 -point 
at baseline achieving ≥4 -point improvement in 
DLQI  from baseline at Week s 16 and 24 for 
participants ≥16 years of age at baseline   
 Change in cDLQI from baseline to Week s 16 
and 24 for participants <16 years of age at 
baseline  
 Percentage change in SCORAD from baseline 
to Week s 16 Week 24   
Abbreviations: A D = atopic dermatitis; cDLQI = Children’s Dermatology Life Quality Index ; DLQI = Dermatology 
Life Quality Index; EASI = Eczema Area and Severity Index; EASI -75 = ≥75% reduction from baseline in EASI; 
EASI -90 = ≥90% reduction from baseline in EASI; IGA = investigator’s global assessment ; NRS = numeric rating 
scale; Q2W = once every 2 weeks; SCORAD = SCORing atopic d ermatitis .  
NOTE: Endpoints in the table above collected by [CONTACT_81238].  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88447] is: What is the intervention effect in percentage of 
participants achieving EASI -75 after 16 weeks of lebrikizumab 250  mg once every 2 weeks 
(Q2W ) intervention in participants with moderate -to-severe AD, who have been previously 
treate d with dupi[INVESTIGATOR_81171] 16.  
The estimand is described by [CONTACT_6570]:  
Population: participants with moderate -to-severe AD who have been previously treated with 
dupi[INVESTIGATOR_81172] u ntil Week 16 .  
Further details can be found in Section 5. 
Endpoint: Do participants achieve at least 75% improvement from baseline to Week 16 in EASI . 
Intercurrent events: There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment. Therefore, 
participants who stay on study treatment through Week [ADDRESS_88448] an intercurrent event 
such as initiating rescue medication or permanently discontinuing treatment .  
Population -level summary: Percentage of participants achieving EASI -75 response  at Week 16.  
Secondary estimand(s)  
There is no secondary estimand planned at this stage, however, additional estimand (s) might be 
specified in the statistical analysis plan ( SAP).  
Overall Design  
Study J2T-MC-KGBO (KGBO ) is an open -label, Phase 3b study, which is 24  weeks in treatment 
duration. The study is desi gned to evaluate the safety  and efficacy of lebrikizumab in adults and 
adolescent s (≥12 years to <18 and weighing ≥40 kg)  with moderate -to-severe AD  and previous ly 
treated with  dupi[INVESTIGATOR_12458] . 
During the 24 -week Treatment Period , approximately 120 participants will receive treatment:  
 500 mg subcutaneous (SC) once every 2 weeks ( Q2W ) loading dose at baseline and 
Week 2, followed by 250 mg SC Q2W  until Week 16 . 
 Responders, defined as achieving IGA (0,1) or EASI -75 at Week 16, will receive 250 mg 
SC once every 4 weeks ( Q4W). 
 Inadequate responders at Week 16 will continue to receive 250 mg SC Q2W.  
 
Brief Summary:  
The purpose of this study is to determine the proportion  of participants achieving EASI -75 at 
Week 16  with lebrikizumab in participants with moderate -to-severe AD  previous ly treated with  
dupi[INVESTIGATOR_12458] .  
Study details include:  
● The planned study duration will be up to 38 weeks .  
● The treatment duration will be up to 24 weeks.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
13 ● The visit frequency will be every [ADDRESS_88449] 2 visits, then every 4 weeks 
thereafter.  
Number of Participant s: 
Approximately 120 participants previous ly treated with dupi[INVESTIGATOR_81173]. Among those, a pproximately 80 participants  will be enrolled who discontinued 
dupi[INVESTIGATOR_81174] : a) no response  to treatment , b) a partial response  to treatment , or c) who lost 
response  to treatment.  Additionally,  approximately 15 participants  will be enrolled who 
discontinued dupi[INVESTIGATOR_81175]  (AEs) . Finally, 
approximately  25 participants  will be enrolled who stopped dupi[INVESTIGATOR_81176] ( for example , cost, in surance coverage , access to medi cation , previous trial participants ). 
Approximately  10% (n=12) of participants will be  adolescents ([ADDRESS_88450] 40 kg) .  
Intervention Groups  and Duration : 
Lebrikizumab drug product is provided as sterile liquids and contain no preservatives.  
Intervention Name  [CONTACT_81294]  250 mg (125 mg/mL), 2  mL Solution  
Dosage Level  Loading Dose:  
Week 0 : 500 mg ( 2 injections of 250 mg ) 
Week 2 : 500 mg ( 2 injections of 250 mg ) 
 
Post-loading dose:  
Week s 4-16: 250 mg SC Q2W (1 injection  of 250 mg )  
Responders at Week 16 : 250 mg SC Q4W  (1 injection of 250 mg ) at W20  
Inadequate responders  at W eek 16: 250 mg SC Q2W  (1 injection of 250  mg) 
at W18, W20, and W2 2 
Route of Administration  SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = once every 2 weeks ; Q4W = once 
every 4 weeks ; W = week . 
Data Monitoring Committee: No 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
14 1.2. Schema   
 
Abbreviations: EASI = Eczema Area and Severity Index ; IGA = Investigator’s Global Assessment ; n = number; Q2W = once every 2 weeks; Q4W = once every 
4 weeks; SC = subcutaneous ; W = week . 
a Week s 12 and 20  are phone visits .  
b 30-day screening window . 
c Lebrikizumab loading dose of 500 mg SC will be administered at baseline and Week 2.  
d Responders: Participants  who reach IGA 0 or 1 (clear or almost clear) or a 75% reduction in the EASI score from baseline (EASI -75). Inadequate responders  
are p articipants  who do not reach these  criteria . 
e The safety follow -up visit will occur approximate ly [ADDRESS_88451] study intervention injection . 
 
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
15 1.3. Schedule of Activities  (SoA)   
 Period I   Period II  Period III  Comments  
Screening  Baseline  Treatment Period  Post-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88452] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±[ADDRESS_88453] dose of study 
intervention.  
Demographics  X           Includes:  
 ethnicity, sex , and race  
 full date of birth for participants 12 -17 
years of age , and  
 year of birth for participants ≥[ADDRESS_88454] 
surgical and medical history should be 
collected.   
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88455]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88456] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
Prespecified 
medical history 
(indication and 
history of interest)  X           Additional data for the indication and 
comorbidities of interest are collected , 
(including conjunctivitis and facial dermatitis) .  
Record prior 
treatments for 
indication  X           Includes medications and therapi[INVESTIGATOR_81177].  
Review 
immunization 
record  X           The investigator should review the vaccination 
status of each pediatric participant <18 years of 
age to assess if the participant is up to date with 
immunizations following the local guidelines 
for vaccination with vaccines intended to 
prevent infectious d isease prior to enrolling 
participants into the study.  
For participants who are under -vaccinated, the 
investigator should document the benefit  or 
risk rationale for enrolling the participants in 
the study.  
Review menarche 
status with date of 
menarche (if  
applicable)  X X X X X   X   X X   For participants <18 years of age.  
If the participant reaches menarche at any time 
during the trial and is sexually active, 
pregnancy testing and contraception 
requirements will apply. See Section 10.4, 
Appendix 4 .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88457]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88458] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±[ADDRESS_88459] 5 min utes. 
Use size appropriate blood pressure cuffs.  
Physical 
examination  X        X X  The physical exam ination  is performed 
(excludes pelvic and rectal, unless clinically 
indicated) . Full skin exam ination  is required for 
BSA calculation.  
Symptom -
directed physical 
assessment   X X X X  X    X As indicated based on participant status and 
standard of care. May be performed by 
[CONTACT_81239].  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88460]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88461] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
Participant Diary (Electronic)  
Diary  dispensed  X           Diary includes daily collection of PRO 
assessments (Pruritus NRS, Sleep -Loss Scale, 
and Skin Pain NRS); bi -weekly collection of 
study drug administration information (as 
applicable) . TCS usage will be collected daily 
beginning at V2.   
Pruritus NRS an d Sleep -Loss Scale should be 
completed a minimum of 4 of 7 days before 
baseline . 
Review diary for 
completion of 
PRO and TCS  
assessments   X X X X X X X X X  For details of these assessments see Section  
8.1. 
Drug 
administration  
diary compliance 
check      X X X X X X   
Diary return          X X   
PROs  (Electronic)  
Complete prior to any clinical administered assessments   
DLQI   X     X  X X  Only for participants ≥16 years of age at 
baseline.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88462]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88463] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
cDLQI   X     X  X X  Only for participants <[ADDRESS_88464]   X  X   X  X X    
Participant -
Reported 
Satisfaction 
Question        X  X X   
Clinical -Administered Assessments (Electronic)  
IGA X X X X X  X  X X   
F-IGA  X X X X  X  X X   
EASI  X X X X X  X  X X   
BSA  X X X X X  X  X X   
mTLSS   X  X   X  X X   
SCORAD   X     X  X X   
Clinical -Administered Assessments (Paper)  
Fitzpatrick Skin 
Type Assessment   X           
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88465]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88466] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
Participant Education and Supplies  
Participant  or 
caregiver 
instructions on 
diary completion  X           Education can also be performed , as needed.  
Remind 
participant of 
TCS usage 
restrictions and 
expectations  X           Required 2 week wash out of TCS prior to 
Visit 2. See Section 6.8.1  for TCS usage during 
the study . 
Train participant 
and/or caregiver 
on study 
intervention 
administration    X X        Participants and/or caregivers need to be 
adequately trained on injection technique prior 
to administering injections.  
Training can be done at Week 2 and/or Week 4 
prior to self -administration.  
Dispense ancillary 
supplies for at 
home dosing     X X  X      
Laboratory Tests and Sample Collections  
Hematology  X X  X   X  X X X  
Clinical chemistry  X X     X  X X X  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88467]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88468] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±[ADDRESS_88469] 
dose of study intervention for females ≥[ADDRESS_88470] dose of study 
intervention. See Section 10.4, Appendix 4.  
Urine pregnancy 
(local)   X  X X  X  X X  Collect for WOCBP only. Done locally and 
prior to administering study intervention .  
Additional pregnancy tests (beyond those 
required per the SoA) should be performed at 
any time during the trial if a menstrual period is 
missed, there is clinical suspi[INVESTIGATOR_81178] . See Section 10.4, Appendix 4.  
If required per local regulations and/or 
institutional guidelines, pregnancy testing can 
occur  at other times during the study treatment 
period.  
HIV screening 
tests X            
HCV screening 
tests X           If anti -HCV is positive, it must be followed by 
a HCV RNA test. See Section 8.2.4.  
HBV  screening  
tests X           Includes testing for HBsAg,  
HBcAb  and HBsAb . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88471]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88472] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±[ADDRESS_88473] an additional unscheduled sample 
as detailed in Section 8.4.  
Immunogenicity 
(ADA) samples   X  X     X X  Samples to be collected pre dose. 
If an immediate or nonimmediate systemic drug 
hypersensitivity reaction occurs in any participant 
then also collect an additional unscheduled sample 
as detailed in Section 10.2.[ADDRESS_88474] predose . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88475]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88476] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
Registration and Dosing  
Register visit with 
IWRS  X X X X X X X X X X X  
Dispense study 
intervention via 
IWRS   X X X X  X      
Administer study 
intervention  in 
clinic   X X X X  X     Week 0 (Visit 2) and Week 2, dose to be 
administered in the clinic by [CONTACT_3725].   
Weeks 4, 8, and 16 dosing to be performed in 
clinic administered by [CONTACT_81240].   
Dispense study 
intervention to 
participant for at 
home dosing     X X  X     Injections will be administered by [CONTACT_81241] 6, 10, 12, 
and 14. 
Responders at Week 16 who will receive Q4W 
dose will administer study intervention at 
Week 20.  
Inadequate responders at Week 16 who will 
receive Q2W dosing will administer study 
intervention  at Weeks  18, 20, and 22 . 
Observe 
participant  or 
caregiver 
administer study 
intervention     X         
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88477]-
Treatment 
Follow -up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801  
Week Relative to 
Study Drug Start  ≤30 (days)  [ADDRESS_88478] dose   
Visit Interval 
Tolerance  (Days)  – ±3 ±3 ±5 ±5 ±5 ±5 ±5 - ±7  
Visit Detail      T  T     
Participant returns 
study intervention      X  X  X X  If study intervention was administered at home 
by [CONTACT_81242], the injection 
supplies should be saved and returned at the 
next on -site visit.  
Assess study 
intervention 
compliance      X  X  X    
Abbreviations: AD = atopic dermatitis ; ADA = anti-drug antibod y; ADCT  = atopic dermatitis control tool; AE = adverse event; AESI = adverse event of special 
interest; BSA = body  surface area ; cDLQI = Children’s Dermatology Life Quality Index ; DLQI  = Dermatology Life Quality Index ; DNA = deoxyribonucleic 
acid; EASI = Eczema Area and Severity Index; ED = early discontinuation; F-IGA = face-IGA; HBcAb = hepatitis B core antibody ; HBsAb  = hepatitis B 
surface antibody; HBsAg = hepatitis B surface antigen ; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; ICF = 
informed consent form; IgE = immunoglobulin E; IGA = investigator ’s global assessment; IWRS = interactive web -response  system; mTLSS = Modified  
Total Lesion Symptom Scale; NRS = numeric rating scale; PK = pharma cokinetics ; PRO = patient -reported outcome; Q2W = once every 2 weeks; Q4W = 
once every 4 weeks; RNA = ribonucleic acid ; SCORAD = SCORin g atopic dermatitis ; T = Telephone;  TCS = topi[INVESTIGATOR_11977] s; WOCBP = women of 
child -bearing potential;  WPAI -AD = Work Productivity and Activity Impairment Questionnaire - Atopic Dermatitis .
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
25 2. Introduction   
Lebrikizumab (LY3650150) is a monoclonal antibody based on the immunoglobulin G4 
antibody stabilized by a mutated Fc region. Lebrikizumab binds with high af finity  specifically to 
soluble interleukin ( IL)-13 and blocks IL -13 signaling through the IL-4 receptor alpha ( IL-4R) 
or IL-13 receptor alpha 1 ( IL-13R1) pathway, thereby [CONTACT_81243] -13 with high potency. Blockade of IL -13 signaling is expected to be of benefit in 
diseases in which IL -13 is a key contributor to the disease pathogenesis.  
2.1. Study Rationale   
Atopic dermatitis (AD) is a chronic heterogeneous inflammatory skin disorder  caused by [CONTACT_81236]. Due to the heterogeneous nature 
of the disease, patients have diverse treatment needs. Standard treatment modalities for the 
management of these patients are centered around the use of topi[INVESTIGATOR_900] -inflammatory 
preparations and skin moisturiz ers, but patients with moderate -to-severe disease may require 
phototherapy or systemic treatment. Dupi[INVESTIGATOR_12458], a monoclonal antibody which inhibits the 
signaling of IL-[ADDRESS_88479] or loss of access ( for example, insurance) to the drug.  Taken together, 
a significant number of patients do not continue dupi[INVESTIGATOR_81179].  In the pi[INVESTIGATOR_81180] 3 trials, 36 % to 38%  of 
participants achieved the primary endpoint of an Investigator’s Global Assessment  (IGA) (0,1) 
with a ≥2 -point reduction in IGA and 44 % to 51%  achieved Eczema Area and Severity Index -75 
(EASI -75) data from baseline to Week  16, indicating that a significant proportion of the patients 
did not  achieve clinical  response. (Simpson et al. 2016 ).  
 
Therefore, there is an important gap in the clinical care of these patients for whom novel 
therapi[INVESTIGATOR_81166].  
In patients with AD, IL -13, a central pathogenic mediator in the disease, is overexpressed, 
driving multiple aspects of AD pathophysiology by [CONTACT_81244] T -helper type 2 (Th2) cell 
inflammation and resulting in skin barrier dysfunction, itch, infection , and lichenification . 
Dupi[INVESTIGATOR_24783] a monoclonal antibody that binds to the shared α chain subunit of the IL-4 and 
IL-13 receptors, thereby [CONTACT_81237]-4 and IL-13. IL -4 is the driver of the 
differentiation of naïve CD4+ T cells into T-helper Type 2 ( Th2) cells and a negative regulator of 
T-helper Type 1 ( Th1) and T-helper Type 17 ( Th17 ) pathways. Blockade of Th2 differentiation 
by [CONTACT_81245] a dysregulation in the T -helper balance, providing a mechanistic 
explanation for the development of Th1  or Th17 diseases in dupi[INVESTIGATOR_12458] -treated patients ( Tracey 
et al. 2018 ; Safa and Paumier 2019; Varma and Levitt 2020 ; Heibel et al. 2021).  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
26 IL-13 is considered a key cytokine in AD (Tsoi 2019 and reviewed in Bieber  et al.  2020).  
Lebrikizumab specifically blocks IL -[ADDRESS_88480] when bound to lebrikizum ab, because lebrikizumab does not inhibit the binding of IL -13 
to the decoy receptor, IL -13Rα2. 
Lebrikizumab  Phase 2 and 3 data demonstrated its efficacy in AD. Leveraging data from both 
Phase 2b monotherapy and Phase 3 TCS combination therapy in which dup ilumab  experienced 
patients were included, lebrikizumab showed consistent treatment effects in both dupi[INVESTIGATOR_81181]ïve and dupi[INVESTIGATOR_81182]. Nevertheless, those trials were not designed to 
evaluate this specific patient population.  
This tria l aims to specifically evaluate the safety and efficacy of lebrikizumab in patients 
previous ly treated with  dupi[INVESTIGATOR_12458].  Biologics experienced patients requiring a second biological 
therapy constitute an important and constantly expanding clinical conundrum in immune 
mediated diseases.  The results from this tri al will provide insights into the clinical response in 
this difficult to treat population and its comparison  with the response in dupi[INVESTIGATOR_81170]ïve 
population studied in the pi[INVESTIGATOR_9205] 3 programs.  
2.2. Background   
Atopic dermatitis is a complex heterogen eous disease that is determined by [INVESTIGATOR_18193], 
environmental, and immunologic factors (Werfel et al. 2016; Simon et al. 2019). Genetic studies 
of AD (Bieber 2012; Auriemma et al. 2013; Weidinger et al. 2018) have shown that genes 
encoding for cytokines involved in the regulation of the immune syst em (IL -4, IL -5, and IL -13) 
are strongly associated with the development of AD (Novak et al. 2002; He et al. 2003; 
Hummelshoj et al. 2003). In addition, variants of genes that encode for proteins involved in skin 
barrier function such as filaggrin (FLG) and  loricrin (LOR) are also associated with AD (Van 
Bever and Llanora 2011). Since FLG plays a central role in skin barrier integrity, loss of function 
mutations of the FLG gene are considered a major contributor to the development of early 
childhood AD (Bieb er 2008; Tanei 2009; Bieber 2012; Flohr and Irvine 2013).  
Reduced epi[INVESTIGATOR_81183], which represents the first line of protection against the 
environment, is thought to lead to sensitization to environ mental allergens, associated with 
elevated immunoglobulin E  (present in about 50% to 80% of all patients with AD ), particularly 
in children (Werfel et al. 2016) and consistent with the presence in the skin of Type  2 cytokines 
(IL-4, IL -5, IL -9, IL -13, IL -25, IL -31, IL -33, and thymic stromal lymphopoietin) and 
inflammation. Type 2 cytokines increase epi[INVESTIGATOR_81184], sensitization, inflammation, 
pruritus  and decrease the expression of antimicrobial peptides and the barrier proteins FLG, 
LOR, and involucr in (Caretti et al. 2015).  IL-13 in particular can reduce epi[INVESTIGATOR_81185], LOR, and involucrin (Kim et al. 2008) and can 
act on keratinocytes in the skin to downregulate their differentiation (Howell e t al. 2008). IL-13 
also induces T -cell chemoattractants that mediate T -cell infiltration into AD lesions (Purwar et 
al. 2006) and may also induce IL -5 expression and eosinophil infiltration through the induction 
of eosinophil chemoattractants (Esche et al.  2004). Increased expression of IL -13 has 
consistently been reported in AD skin lesions and is associated with disease severity (Hamid et 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
27 al. 1996; Jeong et  al. 2003; Tazawa et al. 2004; La Grutta et al. 2005; Neis et al. 2006; Choy et 
al. 2012; Suárez -Fariñas et al. 2013). The elevation of IL -13 expression in the nonlesional skin of 
patients with  AD supports the evaluation of anti -IL-13 therapi[INVESTIGATOR_81186] ( Suárez -
Fariñas et  al. 2011) . Itch is one of the predominant  sympto ms in AD and studies hav e shown 
IL-13 acts as a potent neuronal enhancer to itch signals, resulting in amplification of 
histaminergic and non -histaminergic itch in human sensory neurons and driving the persistence 
of heightened chronic itch, as seen in  AD. Miron et al . recently p ublished results from human 
cadaveric neurons stimulated with IL -13, in the absence or presence of lebrikizumab. 
Lebrikizumab blocked the neuronal response to multiple itch stimuli and may be an effective 
treatment for chronic itch (Miron et al . 2022).  
Epi[INVESTIGATOR_81187] -year prevalence of AD among adults is estimated between 2% to 7% in the US, Europe, 
and Japan ( Saeki et al. 2006; Harrop et al. 2007; Diepgen et al. 2016; Sacotte and Silverberg 
2018). Approximately 30% of adult patie nts with AD have moderate -to-severe disease (Bieber 
and Straeter 2015).  
Clinical Manifestations  
Clinically, AD is characterized by [CONTACT_81246], 
papules and/or plaques with scale , lichenification, and intense pruritus (Bieber 2008), which, 
along with the distribution, chronicity, and history of skin lesions, form the basis for making a 
diagnosis of AD. Flares are frequently triggered by [CONTACT_81247], irritants 
and allergens (Bieber and Novak 2009). Several clinical patterns, with differing distributions of 
skin lesions in distinct age groups  and skin types , have been noted (Weidinger and Novak 2016; 
Weidinger et al. 2018).  
Classic AD lesions, which are most commo n in adolescents and adults, present on the antecubital 
and popliteal fossae. Lesions frequently localize to the face and neck, and a considerable portion 
of patients (around 30%) develop atopic hand dermatitis, which may interfere with workplace 
activitie s. Lesions may have associated lichenification and crusting, and patients with AD may 
be at increased risk for bacterial cutaneous superinfection.   
Quality of Life  (QoL)  
Patients with AD have a high disease burden, and their quality of life  (QoL)  is signif icantly 
affected. In one study, AD was shown to have a greater negative effect on patient mental health 
than diabetes and hypertension (Zuberbier et al. 2006). Adolescent patients  with moderate -to-
severe AD have a higher prevalence of social dysfunction an d sleep impairment, which are 
directly related to the severity of the disease (Williams et al. 2008). Depression, anxiety, and 
social dysfunction not only affect adolescent patients with AD but also affect their caregivers 
(Zuberbier et al. 2006). Compared  with patients  with psoriasis, another common and debilitating 
skin disease, adult and adolescent patients with AD have lower physical vitality, social 
functioning, role-emotional, and mental health scores (Kiebert et  al. 2002 ; Langan et al. 2020 ; 
Eckert et al. 2018, 2019 ; Vakharia et al. 2017 ; Silverberg et al. 2018, 2019).  
Treatment for Atopic Dermatitis  
The therapeutic app roach to AD consists primarily of trigger avoidance, skin hydration, and use 
of moisturizers and anti -inflammatory therapi[INVESTIGATOR_81188] 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
28 corticosteroids ( TCS). In many patients, treatment with TCS provides some measure of 
symptomatic relief  but does not always adequately control the disease. In patients not responding 
adequately to TCS, the topi[INVESTIGATOR_81189]-up options include phototherapy and systemic 
immunosupp ressive agents such as oral or injected corticosteroids, cyclosporine, azathioprine, 
methotrexate, and mycophenolate mofetil. In 201 7, dupi[INVESTIGATOR_12458], a monoclonal antibody  that binds 
specifically to the shared α chain subunit of the IL-4 and IL-13 receptors, t hereby [CONTACT_81248]-4 and IL-13, was approved for the treatment of adult patients with moderate -to-
severe AD  (Seegräber  et al. 2018 ; Gooderham et al. 2018). In 2 randomized clinical trials , SOLO 
1 and SOLO 2 , dupi[INVESTIGATOR_81190] 16 weeks of treatment 
across multiple outcome measures that reflected objective signs of AD, subjective symptoms ( for 
example , pruritus), important aspects of mental health ( that is , anxiety and depression), and QoL. 
In these  trials, 36 % to 38%  of participants achieved the primary endpoint of an IGA (0,1) with a 
≥2-point reduction in IGA and 44 % to 51%  achieved EASI -75 data from baseline to Week 16, 
indicating that a significant proportion of the patients did not achieve clini cal response. (Simpson 
et al. 2016).   
In [ADDRESS_88481], tralokinumab, was approved for adults with moderate -to-severe 
AD. Also in 2021, the topi[INVESTIGATOR_81191] (JAK) inhibitor ruxolitinib was approved for the 
treatment of mild to moderate AD in  adults and children age [ADDRESS_88482] available biologic for the treatment of moderate -to-severe  AD, and may 
continue to be widely used. However,  dupi[INVESTIGATOR_81192]; there is a need to fill t his clinical 
care gap  to improve the lives of patients . (Marniquet et al. 2022 and Faiz et al. 2019) . There are 
limited data on  the reasons for d upi[INVESTIGATOR_81193] . A multicenter study confirmed that 
15.5% (150/968)  of patients discontinued dupi[INVESTIGATOR_81194] a 3.5-year period . (Marniquet et al . 
2022)  Reasons for discontinuation included side effects (40.7% ), lack of efficacy (14.7% ), both 
side effects and lack of efficacy (15.3% ), planned pregnancy (8%), disease remission (4%) and 
“other ” (17.3% ). Side effects included ophthalmological (24%), facial erythema (8%), diffuse 
AD exacerbation  (6.7%),  eosinophilia (4%), alopecia areata (2.7%) , psoriasis (2.7%) , headache 
(0.7%), injection site reaction (0.7%)  and “other” (5.3%) . Another French study confirmed that 
of 241 patients taking dupi[INVESTIGATOR_81195] -to-severe AD from 29 centers , 79.7% remained 
on the medication at 6 months.  (Faiz et al . 2019).  Of the 42 patients for which data w ere 
available, reasons for discontinuation included adverse event  (AE) (11.3%), inefficiency (3.8%), 
patient wish (3.4%), pregnancy ( <1%), surgery (1.7%)  and improvement of AD (<1%).  AEs 
included opht halmologic (4 .2%), eosinophilia (2.1%) and “other” ( 5%).  
Lebrikizumab is an IL-[ADDRESS_88483], 
intolerance or AEs, or for other reasons.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of lebrikizumab is 
provided in the Investigator’s Brochure  (IB). 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
29 2.3. Benefit/Risk Assessment   
As of [ADDRESS_88484] received 
lebrikizumab. L ebrikizumab has been given to 525 healthy people and 5849 study participants 
with AD, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and 
Hodgkin’s lymphoma. Approximately [ADDRESS_88485] been treated with lebrikizumab  in the Phase 2 
and Phase 3 AD program s.  
The use of lebrikizumab for the treatment of AD is suppo rted by [CONTACT_81249] -13 in skin. Moreover, 
Phase 2 efficacy studies of lebrikizumab ( J2T-DM-KGAG/TREBLE , J2T -DM-KGAH/ARBAN 
and J2T -DM-KGAF/DRM06 -AD01) demonstrated sig nificant clinical benefit in participants 
with AD. The top -line results from the 2 monotherapy Phase 3 studies of lebrikizumab 
(ADvocate 1 and ADvocate 2) achieved the primary and all key secondary endpoints, including 
skin clearance and itch improvement a t Week [ADDRESS_88486] completed pi[INVESTIGATOR_9205] 3 trial of 
lebrikizumab in combination with topi[INVESTIGATOR_8826] (ADhere) also met all primary and key 
secondary endpoints at Week 16.  
Potential risks associated with lebrikizumab include conjunctivi tis, eosinophilia and eosinophilic 
conditions, herpes zoster and herpes infections (Section 8.3.3 ), anaphylaxis and hypersensitivity 
reactions (Section 8.3.4 ), and other infections (Section [IP_ADDRESS] ).  
In the initial [ADDRESS_88487] common AEs 
included conjunctivitis, nasopharyngitis , and headache for lebrikizumab -treated patients. 
Discontinuations due to AEs were similar in the lebrikizumab group (1.4%) compared to pl acebo 
(1.7%). The safety profile of lebrikizumab observed in the [ADDRESS_88488] trial-level safety reviews at periodic intervals throughout the study.  
In summary, in the context of the cumulative knowledge for lebrikizumab, the benefit/risk 
balance is assessed to be acceptable for testing in this Phase 3b study.  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of lebrikizumab  may be found in the IB or Development Safety Update Report . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
30 3. Objectives , Endpoints , and Estimands   
Objectives  Endpoints  
Primary   
 To evaluate efficacy of  
lebrikizumab 250 mg Q2W  on 
reduc ing signs and symptom s 
of AD at Week 16 in 
participants with moderate -to-
severe AD  previous ly treated 
with dupi[INVESTIGATOR_12458]   Percentage of participants achieving EASI -
75 at Week 16  
Secondary   
 To evaluate the efficacy of 
lebrikizumab on reducing signs 
and symptoms of AD at  Week 
16 and Week 24 in participants 
with moderate -to-severe AD  
previous ly treated  with 
dupi[INVESTIGATOR_12458]   Percentage of participants achieving EASI -
75 at Week 24  
 Percentage of participants with an IGA 
score of 0 or 1 and a reduction ≥2 points 
from baseline to Week s 16 and 24   
 Percentage change EASI from baseline to 
Week s 16 and 24  
 Change in EASI from baseline to Week s 16 
and 24  
 Percentage of participant achieving EASI -
90 from baseline to Week s 16 and 24  
 Percentage of participants with a Pruritus 
NRS of ≥[ADDRESS_88489] 4 -point reduction at Week s 16 and 24  
 Percentage of participants with a Pruritus 
NRS of ≥ [ADDRESS_88490] 3 -point reduction  at Week s 16 and 24  
 Percentage change in Pruritus NRS score 
from baseline to Week s 16 and 24  
 Percentage of participants  with a Sleep -Loss 
Scale of ≥[ADDRESS_88491] 2 -point reduction at Week s 16 and 
24  
 Change in Sleep -Loss Scale from baseline 
at Week s 16 and 24  
 Percentage  of participants  with a Skin Pain 
NRS of ≥4  points at baseline who achieve a 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88492] ion from baseline at Week s 
16 and 24   
 Change in Skin Pain NRS from baseline to 
Week s 16 and 24   
 Change in DLQI from baseline to Week s 16 
and 24 for participants ≥16 years of age at 
baseline  
 Percentage of participants  with at least 
4 point at baseline achieving ≥4 -point 
improvement in DLQI from baseline at 
Week s 16 and 24 for participants ≥16 years 
of age at baseline  
 Change in cDLQI from baseline to Week s 
16 and 24 for participants <16 years of age 
at baseline  
 Percentage change in SCOR AD from 
baseline to Week s 16 and 24   
Exploratory   
To evaluate the efficacy of lebrikizumab in 
participants with moderate -to-severe AD  
previous ly treated with  dupi[INVESTIGATOR_12458]   Percentage  change from baseline in mTL SS 
(hands) at Week s 16 and 24  
 Percentage change in ADCT from baseline 
by [CONTACT_765]  
 Proportion of TCS/TCI -free days from 
baseline to Week s 16 and 24  
 Using WPAI -AD by [CONTACT_765], change in 
baseline in:  
 absenteeism, in those who are 
currently employed (working for 
pay)  
 presenteeism, in those who are 
current ly employed (working for 
pay),   
 overall work impairment, in those 
who are currently employed 
(working for pay),   
 impairment in activities  (all 
participants) 
 Percentage of participants with an F-IGA 
score of 0 or 1 and a reduction ≥[ADDRESS_88493] 2 points  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
32  Percentage of participants achieving EASI -
75 by [CONTACT_765]  
 Percentage of participants with an IGA 
score of 0 or 1 and a reduction ≥2 points 
from baseline by [CONTACT_765]  
 Percentage change in EASI by [CONTACT_765]  
  Change in EASI by [CONTACT_765]  
 Percentage of participants achieving EASI -
90 by [CONTACT_765]  
 Percentage of participants with a Pruritus 
NRS of ≥4  points at baseline who achieve a 
4-point reduction by [CONTACT_765]  
 Percentage of participants with a Pruritus   
NRS of ≥ 3 points a t baseline who achieve a 
3-point reduction by [CONTACT_765]  
 Percentage change in Pruritus NRS score 
from baseline to Week s 16 and 24  
 Percentage of participants with a Sleep -Loss 
Scale of ≥2  points at baseline who achieve a 
2-point reduction by [CONTACT_765]  
 Change in Slee p-Loss Scale from baseline 
by [CONTACT_765]  
 Percentage of participants with a Skin Pain 
NRS of ≥4  points at baseline who achieve a 
4-point reduction from baseline by [CONTACT_765]  
 Distribution of responses for participant 
satisfaction (1 question)  at Week s 16 and 24   
To discern responder variability within the study 
and to track response variability to lebrikizumab  Changes from baseline in  serum proteins related to AD 
pathogenesis ; Refer to Section 10.2, Appendix 2 
Abbreviations:  AD = atopic dermatitis ; ADCT = atopic dermatitis control tool; cDLQI  = Children ’s Dermatology 
Life Quality Index ; DLQI  = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index ; EASI -75 = 
≥75% reduction from baseline in EASI; EASI -90 = ≥90% reduction from baseline in EASI; F-IGA = face - 
investigator’s global assessment ; IGA = investigator’s global assessment ; mTL SS = Modified Total Lesion 
Symptom  Scale; NRS = numeric rating  scale; Q2W = once every 2 weeks ; SCORAD = SCORing atopic dermatitis ; 
TCI = topi[INVESTIGATOR_22726] , TCS = topi[INVESTIGATOR_11977] ; WPAI -AD = work productivity and activity 
impairment questionnaire –atopic dermatitis.  
NOTE:  Endpoints in the table above collected by [CONTACT_81238].  
Primary estimand  
The primary clinical question of interest is: What is the intervention effect in percentage  of 
participants achieving EASI -75 after 16 weeks  of lebrikizumab 250  mg once every 2 weeks 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
33 (Q2W ) intervention  in participants with moderate -to-severe AD, who have been previously 
treated with  dupi[INVESTIGATOR_81171] 16 . 
The estimand is described by [CONTACT_6570]:  
Population: participants with moderate -to-severe AD who have been previously treated with  
dupi[INVESTIGATOR_81171] 16 .  
Further details can be found in Section 5. 
Endpoint: Do participants achiev e at least 75% improvement from baseline  to Week 16 in EASI . 
Intercurrent events: There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment. Therefore, 
participants who stay on study treatment through Week [ADDRESS_88494] an intercurr ent event 
such as initiating rescue medication or permanently discontinuing treatment . Further details on 
study interventions and concomitant medications, including rescue  treatments , can be found in 
Section 6.8.1 . 
Population -level summary: Percentage of participants achieving EASI -75 response  at Week 16.  
 
Secondary estimand(s)  
There is no secondary estimand plan ned at this stage, however, additional estimand (s) might be 
specified in the SAP.  
 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
34 4. Study Design   
4.1. Overall  Design   
Study J2T-MC-KGBO ( KGBO ) is an open -label, phase 3b study, which is [ADDRESS_88495] been previously 
treated with dupi[INVESTIGATOR_12458] . 
Study Periods  
This trial has 3 study periods:  
 Screening (Visit 1:  ≤30 days prior to baseline ) 
 Treatment (Visits 2 -9: 24 weeks)  
 Safety follow -up (Visit 801: approximately [ADDRESS_88496]  treatment)  
Visit Types  
Study visits at Week 12 (Visit  6) and Week 20 (Visit 8) will be performed virtually , that is , via 
telephone or telemedicine tools . 
All other visits will be conducted at the clinical trial site . 
Dosing  
During the 24 -week Treatment Period, approximately 120 participants will receive treatment:  
 500 mg subcutaneous ( SC) once every 2 weeks ( Q2W ) loading dose at baseline and 
Week 2, followed by 250  mg SC Q2W  until Week 16. 
 Responders, defined as achieving IGA (0,1) or EASI -75 at Week 16, will receive 250 mg 
SC Q 4W. 
 Inadequate  responders at Week 16 will continue to receive 250 mg SC Q2W.   
The study population is described in Section 5. 
The efficacy and safety assessments are described in Sections 8.1 and 8.2 respectively.  
4.2. Scientific Rationale for Study Design   
The top -line results from 2 randomized controlled monotherapy phase 3 studies of lebrikizumab 
(ADvocate 1 and A Dvocate 2) and a third completed phase 3 trial of lebrikizumab in 
combination with topi[INVESTIGATOR_8826] (ADhere) demonstrated positive risk benefit in adult and 
adolescent patients with moderate -to-severe AD at Week 1 6. The safety profile of these 3 studies 
was consistent with prior AD lebrikizumab studies and demonstrated  favorable benefit : risk 
profile  in moderate -to-severe AD patients . Additional detailed discussion of the lebrikizumab 
studies (preclinical and clinical ) is provided in the lebrikizumab IB.  
Since randomized controlled data is already available, this study will be conducted as an open 
label study to mimic the real-world  patient experience . Week [ADDRESS_88497] Week 1 6. 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88498] taken  dupi[INVESTIGATOR_81196] -to-severe AD;  it is possible that many of these patients may have more 
difficult to treat AD and they may therefore  need adjunct topi[INVESTIGATOR_81197]. To make the study closer to a real world -setting and also to avoid participant  
discomfort, use of mild/moderate potency topi[INVESTIGATOR_8826]/ topi[INVESTIGATOR_22726] 
(TCI)/topi[INVESTIGATOR_81198] -4 (PDE4 ) inhibitors  will be allowed during the study . 
4.2.1.  Participant Input into Design   
Throughout this protocol, the term “participant” is used to indicate an individual who participates 
in a clinical trial, either as a recipi[INVESTIGATOR_81199] a control. This usage  
reflects preferences indicated by [CONTACT_81250].  
No participant input was provided for this study design.  
4.3. Justification for  Dose   
The lebrikizumab dosing regimen of 500  mg loading dose at baseline and Week 2, followed by 
250 mg Q2W up to, and including Week 16, was selected based on an evaluation of safety, 
efficacy, and PK data from the Phase 2 and Phase 3 lebrikizumab trials.  
In the lebrikizumab Phase 3 programs, IGA 0/[ADDRESS_88499] Week 16 are based on the results of the se Phase 3 
studies.  
Adolescent Participants  
In this phase 3b study, adolescent participants (≥12 to <18 years weighing ≥40 kg) will be 
included and will receive the same doses of lebrikizumab as adult participants. PK analyses of 
SC doses of lebrikizumab r eveal similar kinetics for adults and adolescents ≥12 to <[ADDRESS_88500] ed in this age group compared to adults based on partial extrapolation and 
propose to include adolescent participants in this study. It is expec ted that the adolescent AD 
participants ≥[ADDRESS_88501] scheduled procedure shown in the SoA.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88502] scheduled  procedure shown in the Schedule of Activities (SoA) for the last participant in the 
study . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
37 5. Study Population   
Prospective approval of protocol deviations to recruitment and enroll ment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be ≥12 years of age inclusive at the time of signing the informed 
consent/assent.  
Type of Participant and Disease Characteristics  
2. All participants must have prior treatment with dupi[INVESTIGATOR_81200]:  
 Participants who stopped dupi[INVESTIGATOR_81201] -response, partial 
response, loss of efficacy must have been previously treated with dupi[INVESTIGATOR_12458] (at 
labeled dose level) for at least 4 months.  
 Participants who stopped dupi[INVESTIGATOR_81202].   
 Participants who stopped dupi[INVESTIGATOR_81203] (for example, insurance coverage) may enter the study with no 
required prior length of dupi[INVESTIGATOR_24736].   
3. Participants who have chronic AD (according to American Academy of Dermatology 
Consensus Criteria; Eichenfield et al. 2014) that has been present for ≥[ADDRESS_88503] EASI ≥[ADDRESS_88504] IGA score ≥3 (Scale of 0 to 4) at the baseline visit .  
6. Have ≥10% body surface area (BSA) of AD involvement at the baseline visit  
7. Have a history of inadequate response to treatment wi th topi[INVESTIGATOR_5910]; or 
determination that topi[INVESTIGATOR_12432] . 
Weight  
8.  Adolescents  body weight must be ≥40 kg  at baseline . 
Sex and Contraceptive / Barrier Requirements  
9. Male and/or female  
a. Male participants are not required to use any  contraception except in compliance 
with specific local government study requirements.  
b. Female participants of child -bearing  potential: must agree to remain  abstinent 
(refrain from heterosexual intercourse) or use a highly effective contraceptive 
method during the treatment period and for at least [ADDRESS_88505] dose of 
study drug. Women of non -child -bearing  potential (non -WOCBP) may participate 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
38 without any contraception requirements. For definitions of women of child -
bearing  potential (WOCBP) and non -WOCBP, see Section 10.4, Appendix  4. 
Contraceptive use by [CONTACT_81251].  For the contraception 
requirements of this protocol, see Section 10.4, Appendix 4. 
Informed Consent  
10. Informed consent/ assent  
a. For adult participants: capable of giving signed informed consent as described in 
Section 10.1, Appendix 1, which includes compliance with the requirements and 
restrictions listed in the informed consent form (ICF) and in this protocol.  
b. For adolescent participants: a parent or legal guardian must be able to read, 
understand, and give documented informed consent for a child to participate in 
this study as described in Section 10.1.3 , which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol.   
NOTE: Adolescents reaching the age of maturity  while on study must provide 
consent  to continue participation in the study.  
Other Inclusions  
11. Are willing and able to comply with all clinic visits and study -related procedures and 
questionnaires . 
5.2. Exclusion Criteria   
Participants are excluded from the study if a ny of the following criteria apply:  
Medical Conditions  
12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at 
screening.  
13. Have a current infection or chronic infection with hepatitis B virus ( HBV ) at screening 
(that is, positive for hepatitis B surface antigen and/or polymerase chain reaction  positive 
for HBV DNA Section 8.2.3). 
14. Have a current infection with hepatitis C virus ( HCV ) at screening (that is, positive for 
HCV RNA Section 8.2.4). 
15. Have an uncontrolled chronic disease that might require multiple intermittent uses of oral 
corticosteroids  at screening , as defined by [CONTACT_093].  
16. Have uncontro lled asthma that  
a. might require bursts of oral  or systemic corticosteroids, or  
b. required the following due to ≥1 exacerbations within 12 months before baseline  
i. systemic (oral and/or parenteral) corticosteroid treatment, or  
ii. hospi[INVESTIGATOR_272] >[ADDRESS_88506]  known liver cirrhosis and/or chronic hepatitis of any etiology.  
18. History of malignancy, including mycosis fungoides  or cutaneous  T-cell lymphoma , 
within 5 years before the screening, except completely treated in situ carcinoma of the 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88507] a known or suspected history of immunosuppression, including history of invasive 
opportunistic infections ( for example , tuberculosis, histoplasmosis, listeriosis, 
coccidioidomycosis, pneumocystosis, and aspergillosis) despi[INVESTIGATOR_12468]; or 
unusually frequent, recurrent, or prolonged infections, per the investigator ’s judgment.  
21. Have presence of skin comorbidities that may interfere with study assessments . 
22. Have a severe concomitant illness(es) that in the investigator’s judgment would adversely 
affect the participant ’s participation in the study.  
23. Have any other medical or psychological condition that in the opi[INVESTIGATOR_81204] a new and/or insufficiently understood disease, may present an unreasonable 
risk to the study participant because of their participation in this clinical trial, may make 
participant ’s participation unreliable, or may interfere with study assessments.  
24. Have had any of the following types of infection within 3 months of screening or develop 
any of these infections during screeni ng 
a. Serious (requiring hospi[INVESTIGATOR_059], and/or intravenous or equivalent oral antibiotic 
treatment ) 
b. Opportunistic (as defined in Winthrop et al. 2015 , see Section 10.9, Appendix  9) 
NOTE: Herpes zoster is considered active and ongoing until all vesicles are dry 
and crusted over  
c. Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer ) 
d. Recurring (including, but not limited to recurring cellulitis, chronic osteomyelitis)  
 
NOTE:  Participants with only recurrent, mild and uncomplicated orolabial and/or 
genital herpes may be discussed with the sponsor ’s medical monitor to determine 
whether the participants meet this exclusion criterion.  
25. Have an active or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit 
(baseline ; Visit 2), or sup erficial skin infections within 1 week before the baseline visit.  
NOTE:   
Participants may be rescreened after infections resolves.   
Participants who have an upper respi[INVESTIGATOR_4416], a vaginal candida infection, 
or an oral candida infection and who are  being treated only symptomatically and 
not requiring systemic anti-infectives  may be considered for enrollment if other 
study eligibility criteria are met. Enrollment of participants with other 
uncomplicated local infections should be discussed with the sponsor ’s designated 
medical monitor.  
Prior /Concomitant Therapy  
26. Dupi[INVESTIGATOR_81205] 4 weeks prior to the baseline visit.  
27. Prior treatment with tralokinumab . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
40 28. Treatment with topi[INVESTIGATOR_12450] (corticosteroids, calcineurin inhibitors, JAK inhibitors, or 
phosphodiesterase -4 inhibitors ) within [ADDRESS_88508] AD within 4 weeks prior to 
the baseline visit : 
a. systemic immunosuppressive /immunomodulating drugs ( for example , systemic 
corticosteroids, cyclosporine, mycophenolate  mofetil, IFN -gamma , azathioprine, 
methotrexate, and other immunosuppressants );  
b. small molecules (for example,  JAK inhibitors);  
c. phototherapy and photochemotherapy for AD.  
30. Have regularly used (more than 2 visits per week) a tanning booth or parlor within 4 
weeks  of the screening visit (Visit 1).  
31. Are currently receiving build -up dosing of allergen immunotherapy (allergy shots).  
32. Treatment with B cell-depleting biologics, including rituximab, within [ADDRESS_88509] dose of study intervention.  
NOTE : The following are not considered live vaccines: RNA vaccines, vaccines with 
inactive viral elements, and/or non -replicating  viral vector vaccines.  
36. Use of cannabis or cannabinoids for the treatment of pruritus, pain and /or AD. 
Diagnostic Assessments  
37. In the opi[INVESTIGATOR_871], have clinically significant laboratory results from the 
chemistry  or hematology tests  obtained  at the screening visit (Visit 1) .  
Prior /Concurrent Clinical Study Experience  
38. Are currently enrolled i n any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study.  
39. Treatment with an investigational drug within 8 weeks or within 5 half -lives (if known), 
whichever is longer  prior to the baseline visit.  
40. Have received a dose of lebrikizumab in any prior lebrikizumab clinical study . 
Other Exclusions  
41. Are Lilly employees (or are employees of any third -party involved in study who require 
exclusion of the ir employees ). 
42. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88510] a known hypersensitivity to any component of lebrikizumab.  
45. Participant or caregiver who is unwilling to administer SC injections of study medication.  
5.3. Lifestyle Considerations   
Not applicable.  
5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials  publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious adverse event  (SAE) . 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened  as defined below . Rescreened participants should be assigned a new participant 
number for every screening  or rescreening event.   
5.4.1.  Rescreening for Ind ividuals Who Failed Screening   
Informed consent for rescreenings  
Individuals who are to be rescreened must first sign a new ICF /assent form  as applicable  
(Section 10.1, Appendix  1, Section 10.1.3 ). Such individuals will be assigned a new participant 
numb er. 
Rescreening after failure to meet study entry criteria  
An individual who does not meet the criteria for participation in this study for any reason may be 
rescreened one time .  
When rescreening, all of the screening tests and procedures should be repeat ed.  
5.5. Criteria for Temporarily Delaying Enrollment/Administration of 
Study Intervention of a Participant   
Not applicable . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
42 6. Study Intervention (s) and Concomitant Therapy    
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  
6.1. Study Intervention(s) Administered   
Lebrikizumab drug product is provided as sterile liquids and contain no preservatives.  
Intervention Name  [CONTACT_81294]  250 mg (125 mg/mL), 2 mL Solution  
Dosage Level  Loading Dose:  
Week 0 : 500 mg ( 2 injections of 250  mg) 
Week 2 : 500 mg ( 2 injections of 250  mg) 
 
Post-loading Dose: 
Weeks 4 -16: 250 mg SC Q2W  (1 injection  of 250 mg ) 
Responders  at W eek 16: 250 mg SC Q4W (1 injection of 250 mg)  at W20  
Inadequate responders  at W eek 16: 250 mg SC Q2W (1 injection of 250  mg) 
at W18, W20, and W2 2 
Route of Administration  SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = every 2 weeks ; Q4W = once  every 4 
weeks ; W = week . 
 
6.1.1.  Medical Devices   
1. Lebrikizumab will be administered using a sterile prefilled syringe with needle safety 
device . Each prefilled syringe is intended for a single 2 mL dose (250 mg) administered 
subcutaneously device .  
2. Instructions on how to use the device  will be provided.  
3. All Product Complaints  (PCs)  (including malfunction, use error and inadequate labelling) 
shall be documented and reported by [CONTACT_31819] 
(see Section  8.3) and appropriately managed by [CONTACT_456] . 
6.2. Preparation , Handling , Storage , and Accountability   
1. The investigator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may r eceive study intervention . Only authorized 
study personnel  may supply , prepare,  or administer study intervention , except for study  
intervention intended to be administered by [CONTACT_81252] . All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
43 (manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
3. The investiga tor or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance , that is,  receipt, reconciliation, and 
final disposition records.  
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Study Reference Manual .  
6.3. Measures to Minimize Bias: Randomization and Blinding   
In this open -label study, potential bias will be red uced by [CONTACT_81253]. Adherence to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct . 
The site will contact [CONTACT_81254] -response system (IWRS ), prior to the start of study 
intervention administration and at the primary endpoint  for each eligible participant, to provide 
demographic information  and IGA/EASI results, respectively .  
6.4. Study Intervention Compliance   
Study intervention will be administered under medical supervision by [CONTACT_81255] (Wee k 0, Visit 2) and Week 2 (Visit 3) visits . The dose of stud y 
intervention and study participant identification will be confirmed prior to dispensing study drug. 
The date and time of each dose administered will be recorded in the source documents and will 
be provided to the sponsor as requested.   
Beginning Week 4 ( Visit 4) the participant/caregiver will be encouraged to administer the study 
intervention while in the clinic or at home. Participants may choose to  continue to receive study 
drug injections administered by [CONTACT_81256].  Home 
dosing must be self -administered or given by a caregiver that has received proper injection 
technique training . 
When participants self -administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by [CONTACT_81257], 
counting returned injection supplies, and documented in the source docume nts.  
A record of the number of lebrikizumab injections supplies  dispensed to and administered  by 
[CONTACT_81258].  
6.5. Dose Modification   
Dose modifications of lebrikizumab are not allowed in this study.   
6.6. Continued Access to Study Intervention after the End of the Study   
Lebrikizumab will be made available to eligible participants who complete Visit 9 (Week 24)  via 
the Continued Access addendum , until lebrikizumab is commercially available in the US . Please 
refer to KGBO Protocol Addendum 2 for additional information.  Otherwise, lebrikizumab will 
not be provided after participants exit this study.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
44 6.7. Treatment of Overdose   
For this study, any dose of lebrikizumab  greater than 500 mg (baseline and Week 2) and 250 mg 
Q2W  (Week 4 and beyond)  will be considered an overdose.  
Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the investig ator/treating physician  should:  
● Contact [CONTACT_10990].  
● Evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupted or whether the dose should be 
reduced.  
● Closely monitor the participant for any AE/SAE and laboratory abnormalities 
until lebrikizumab can no longer be detected systemically (at least 18 weeks ). 
6.8. Concomitant Therapy   
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
antacids, and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with:  
● reason for use 
● dates of administration including start and end dates  
● dosage information including dose and frequency for concomitant therapy of 
special interest  
The medical monitor should be contact[CONTACT_81259].  
Participants should be instructed to consult with the investigator prior to initiating any new 
medication (either self -administered non -prescription drugs or prescription therapy prescribed by 
[CONTACT_20904] p hysician) while participating in the study. The investigator is expected to examine the 
acceptability of all concomitant medications, topi[INVESTIGATOR_12469], and dietary supplements taken 
by [CONTACT_81260].  
The use of any concomitant medication must relate to an AE listed on the AE case report form 
(CRF ) or the participant’s medical history, unless the medication is a supplement or used as 
preventive care.  
6.8.1.  Permitted Treatments and Procedures   
The following therapi[INVESTIGATOR_81206]:  
Permitted Concomitant Medications and Vaccines  Comments  
Medications   
Medications for medical conditions other than AD 
(for example , hypertension or diabetes)   
Low and /or mid potency  TCS, TCIs ( for example , 
tacrolimus and pi[INVESTIGATOR_031]), or topi[INVESTIGATOR_22732] -[ADDRESS_88511] be documented in the 
diary  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
45 Permitted Concomitant Medications and Vaccines  Comments  
inhibitors ( for example , crisaborole)  for treatment of 
AD (see Section 6.8.4 ) 
High -potency TCS  for treatment of AD  Permitted up to 10 days  
Non-medicated moisturizers   
Intranasal corticosteroids   
Inhaled corticosteroids and bronchodilators to control 
asthma   
Single intra -articular (bursa, tendons, and ligaments) 
corticosteroid injection   
Non-sedating antihistamines   
Ophthalmic drugs containing antihistamines, 
corticosteroids, or other immunosuppressants   
Allergen immunotherapi[INVESTIGATOR_81207] -infectives /antibiotics  For treatment of acute infections  
Sedating systemic antihistamines including, but not 
limited to, alime mazine, chlorphenamine, clemastine, 
cyproheptadine, diphenhydramine, hydroxyzine, 
ketotifen, and promethazine  On an as needed basis  
 
Systemic/oral sleep aid medications  On an as needed basis  
 
Recreational use of cannabis and cannabinoid (if 
allowed per local regulations/law)  Not allowed  for the treatment of 
pruritus, pain and/or AD   
Vaccines   
Non-live vaccinations  Including non -live SARS -CoV -2 
vaccines, RNA vaccines, vaccines 
with inactive viral elements, and/or 
non-replicating viral vectors that 
are clinically indicated  
Abbreviations: AD = atopic dermatitis; RNA = Ribonucleic acid; SARS -CoV -2 = severe acute respi[INVESTIGATOR_11520] 2 ; PDE -4 = phosphodiesterase -4; TCI = topi[INVESTIGATOR_22726] ; TCS = topi[INVESTIGATOR_030] . 
NOTE:  In the context of this table, “during the study” = from screening to post -treatment safety 
follow -up visit.  
6.8.2.  Prohibited Treatments and Procedures   
The following therapi[INVESTIGATOR_81208]:  
Prohibited Concomitant Medications, 
Vaccinations, and Procedures  Comments  
Medications or procedures   
Systemic corticosteroids (IM, PO, or IV)  NOTE: Any use of systemic 
corticosteroids  will be considered as 
rescue medication (see Section 6.8.5) 
Any investigational drug other than the study 
drug   
 
B cell -depleting biologics, including rituximab   
Other b iologic agents  (other than the study 
interv entions)   
Topi[INVESTIGATOR_81209]  (see Section 6.8.5 ) 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
46 Prohibited Concomitant Medications, 
Vaccinations, and Procedures  Comments  
TCS (high potency)  Use for >[ADDRESS_88512] AD (for example , 
immunosuppressive/immunomodulating drugs such as 
systemic corticosteroids, mycophenolate  mofetil, IFN -
gamma , topi[INVESTIGATOR_2855] , and  systemic  JAK inhibitors, 
cyclosporine, azathioprine, or methotrexate; phototherapy 
or PUVA; or systemic PDE -4 inhibitors)   
Chronic Systemic and topi[INVESTIGATOR_900] -infectives  For chronic tr eatment during the study  
Planned or anticipated major medical procedures 
or surgeries   
Tanning booth/parlor   
Bleach bath   
Use of cannabis or cannabinoids for the 
treatment of pruritus, pain and/or AD   
Vaccines   
Live or live attenuated vaccines, as well as BCG 
vaccine   
Abbreviations: AD = atopic dermatitis; AE = adverse event; BCG = Bacillus Calmette -Guerin; JAK = 
Janus kinase; IFN = interferon; IM = intramuscular; IV = intravenous; PDE -4 = phosphodiesterase -4; 
PUVA = photochemotherapy;  TCS = topi[INVESTIGATOR_11930]; PO = by [CONTACT_1966] . 
 
NOTE:  in the context of this table, “during the study” = from screening to post -treatment safety 
follow -up visit.  
6.8.3.  Non-Medicated Moisturizers   
Participants may apply a stable dose of non -medicated topi[INVESTIGATOR_81210] 
≥[ADDRESS_88513] , then topi[INVESTIGATOR_81211]-potency treatment  if 
needed.  In sensitive skin areas ( that is , face, neck, intertriginous, and genital areas) , only low -
potency topi[INVESTIGATOR_81212].  
If AD lesions re cur or a participant experiences a flare , as needed use of low- and/or mid-
potency TCS , TCI  (tacrolimus or pi[INVESTIGATOR_031]) , and/or topi[INVESTIGATOR_22732]4 inhibitor s (crisaborole ) 
may be initiated at the participant’s discretion  but must be communicated to the investigator and 
documented in the patient diary or as concomitant medications.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88514] 7 days of low/m id potency TCS, TCI and/or topi[INVESTIGATOR_22732]4 
inhibitors . Use of high -potency TCS for more than 10 days is considered rescue therapy 
(Section  6.8.5 ). Participants that receive Rescue therapy  must be discontinued from the study. 
(see Section 7.1). All topi[INVESTIGATOR_81213] . 
6.8.5.  Rescue Medicine  for Atopic Dermatitis   
To be consistent with real  world practice, defined topi[INVESTIGATOR_81214] 
(see Section 6.8.4 ). However, rescue therapi[INVESTIGATOR_81215] s. Escalation to high potency topi[INVESTIGATOR_81216], topi[INVESTIGATOR_81217] s, phototherapy  and/or systemic medications (including but not limited to  
corticosteroids, immunosuppressants,  biologics, small molecules , etc.) for the treatment of AD  
should only occur if participants do not respond adequately after at least 7 days of low/mid 
potency TCS, TCI and/or topi[INVESTIGATOR_22732]4 inhibitors.  Any use of topi[INVESTIGATOR_81218], phototherapy, 
and/or systemic medications will be considered rescue therapy.  Use of high -potency TCS for 
more than [ADDRESS_88515] be discontinued from the study. ( see Section 7.1). 
All rescue medication must be recorded in the CRF.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
48 7. Discontinuation of Study Intervention  and Participant 
Discontinuation/Withdrawal   
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1.  
7.1. Discontinuation of Study Intervention   
When necessary, a participant may be permanently discontinued f rom study intervention. If so, 
the participant will remain in the study to complete procedures for an early discontinuation visit 
and post -treatment follow -up, if applicable , as shown in the SoA.  
A participant should be permanently discontinued  from study  intervention if  
 the participant becomes pregnant during the study  
 in the opi[INVESTIGATOR_871], the participant should permanently discontinue the 
study intervention for safety reasons  
 the participant develops a malignancy , except for successfully treated basal or squamous 
cell skin carcinoma  
 the participant tests positive for HBV DNA (see Section 8.2.3 )  
 the par ticipan t tests positive for HCV  RNA (Section 8.2.4 ) 
 if the participant experiences a hepatic event or liver test abnormality as specified in the 
liver chemis try stoppi[INVESTIGATOR_3418] (see Section 7.1.1 ) 
 the participant develops HIV infection  
 the parti cipant  require s rescue medication treatment for symptoms of AD in the treatment 
period  
 the participant develops any infection that is opportunistic, such as active tuberculosis  
and other infections whose nature or course may suggest an immuno -compromised status , 
and 
 the participant has an AE or an SAE or a clinically significant change in a laboratory 
value that, in the opi[INVESTIGATOR_871], merits discontinuation of study intervention 
and appropriate measures being taken.  
Hepatitis  
 prior to discontinuation of any immunomodulatory and/or immunosuppressive therapy 
due to hepatitis, including study intervention, the participant is to be referred to, 
evaluated, and managed by a specialist physician with expertise in evaluation and 
management of viral hepatitis.  
 the timing of discontinuation from study intervention relative to the initiation of any 
antiviral treatment for hepatitis is to be based on the recommendation of the consulting 
specialist physician, in conjunction with the investigator, and aligned with medical 
guidelines and standard of care.  
Hypersensitivity  
 if the investigator determines that a systemic hypersensitivity reaction has occurred 
related to study intervention administration, the participant may be permanently 
discontinued from the study interventio n, and the sponsor’s designated medical monitor 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
49 should be notified. If the investigator is uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of study intervention 
is warranted, the investigator may consul t the sponsor.  
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_81219] (see Sectio n 8.2.2 ) if 
1 or more of these conditions occur:  
Elevationa Exceptiona 
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_88516] >3x ULN and either TBL >2x ULN or 
INR >1.5  For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL  >2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, and/or rash  
ALP >3x ULN, when the source of increased ALP is 
the liver   
ALP >2.5x ULN and TBL > 2x ULN  For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL  >2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, and rash  
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical 
Evaluation, July 2009 and other consensus guidelines, with minor modifications . 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = internation al normalized ratio; TBL = total bilirubin; ULN = upper limit of normal.  
a All ULN values should be age adjusted (AAULN) for participants <[ADDRESS_88517] results return to baseline and if a self -limiting 
non-drug etiology is identified. Otherwise, study intervention sh ould be discontinued.  
7.1.2.  Temporary Discontinuation of Study Intervention   
Temporary withholding of study intervention is required if the participant meets any of the 
following infection -related criteria during the study:  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
50 ● Serious or opportunistic infections, as defined in Section 5.2. Study intervention is  
to be withheld until resolution of all acute clinical signs and symptoms, and 
completion of all appropriate anti -infective treatment.  
● HBV DNA results that are reported as positive, or as detecting HBV DNA, but 
HBV  DNA is below the level of quantificatio n. In this situation, the sponsor ’s 
designated medical monitor should be contact[CONTACT_81261]’s status. 
HBV DNA testing is to be repeated as soon as is feasible. If HBV DNA is 
confirmed as positive, the participant must be permanently discon tinued from 
study intervention as described in Section 7.1. 
 If a participant <18 years of age loses a clinically significant amount of weight (below 
40 kg), the investigator should assess rationale for weight loss and use clinical judgment 
to determine if the participant should temporarily discontinue the treatment.  
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study  
● at any time at the participant’s  own request  
● at the request of the participant’s  designee (for example, parents or legal 
guardian)  
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrolled in any other clinical study involving an investigational product , or 
enrolled in any other type of medical research judged not to be scientifically or 
medically compatible with this study , and  
● if the participant , for any reason, requires rescue medication or treatment with a 
therapeutic agent that is prohibited by [CONTACT_81262] . In this case , discontinuation 
from the study occurs prior to introduction of the new agent . 
At the time of discontinuing from the study, the participant will complete  procedures for an early 
discontinuation visit and post -treatment follow -up, if applicable, as shown in the SoA. If the 
participant has not already discontinued the study intervention, the participant will be 
permanently discontinued from the study intervention at the time of the decision to discontinu e 
the study.  
If the participant  withdraws consent  for disclos ure of future information, the sponsor  may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, the participant  may reques t destruction of any samples taken and not 
tested , and the investigator must document this in the site study records . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88518] participants who fail to return for a scheduled visit 
or wer e otherwise unable to be followed up by [CONTACT_779].   
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
52 8. Study Assessments and Procedures   
● Study procedures and their timing are summarized in the SoA.   
● Immediate  safety concerns  should be discussed with the sponsor  immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
● Adherence to the study design requirements, including those specified in the SoA, 
is essentia l and required for study conduct.  
● All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participant s screened  and to confirm 
eligibility or record reasons for sc reening failure, as applicable.   
8.1. Efficacy Assessments   
8.1.1.  Eczema Area and Severity Index   
The EASI is an investigator -reported , 20-item scale that evaluates 2 dimensions of AD: extent of 
disease at 4 body regions (head  or neck, trunk, upper and lower extremities) and 4 clinical signs 
(erythema, induration  or papulation, excoriation, and lichenification ). The clinical signs are 
assessed for severity on a scale of 0 (absent) to 3 (severe).  
The scores are added up for each of the 4 body regions. The assigned percentages of BSA for 
each section of the body are 10% for head  or neck, 20% for upper extremities, 30% for trunk, 
and 40% for lower extremities , respectively . Each subtotal score is multiplied by [CONTACT_81263].  
In addition, an area score of 0 to 6 is assigned for each body region, depending on the percentage 
of AD -affected skin in that area: 0 (none), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 
(50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Each of the body area scores is multiplied 
by [CONTACT_23005]. The resulting EASI ranges from [ADDRESS_88519] score 
indicating worse severity of AD (Hanifin et al. 2001).  
Assessors must be trained and certified by [CONTACT_81264] g this assessment. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
8.1.2.  Investigator’s Global Assessment (IGA)   
The IGA is an investigator -reported , single -item scale that rates the severity of the participant’s 
AD. The IGA is composed of a 5 -point scale ranging from 0 (clear) to 4 (severe), and a  score is 
selected using descriptors that best describe the overall appearance of the lesions at a given time 
point.  
Assessors must be trained and certified by [CONTACT_81265]. A 
single assessor should be assigned to each p articipant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
53 8.1.3.  Body Surface Area (BSA)   
BSA is an investigator -reported assessment , which estimates the extent of disease or skin 
involvement of a participant ’s AD. BSA is expressed as a percentage of total body surface and 
will be reported by [CONTACT_81266]. The recall period of this assessment is present  time.  
Assessors must be trained and certified by [CONTACT_81265]. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring.  
8.1.4.  Face -Investigator’s Global Assessment  (F-IGA)   
The F-IGA is an investigator -administered, single -item scale that rates the severity of the 
participant’s AD  on the face.  The F-IGA is composed of a 5 -point scale ranging from 0 (clear) to 
4 (severe), and a score is selected using descriptors that best describe the overall appearance of 
the facial  lesions at a given time point.  
Assessors must be trained and certified by [CONTACT_81267]. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
8.1.5.  SCORing Atopic Dermatitis (SCORAD)   
The SCORAD index is an investigator - and participant -reported , 9-item assessment in both 
adults and adolescent participants that assesses 3  aspects as provided below . 
 The extent  (1-item) of AD is assessed by [CONTACT_1694] a percentage of each defined 
body area and reported as the sum of all areas. The maximum score is 100% . The recall 
period of this scale is present time.  
 The severity of 6 specific symptoms of AD  is assesse d by [CONTACT_093] : erythema, 
edema  or papulation, oozing  or crusts, excoriation, lichenification , and dryness are 
assessed by [CONTACT_55296] a 4 -point scale ( that is , none = 0, mild = 1, moderate = 
2, severe = 3) with a maximum possible total o f 18 points . The recall period of this scale 
is present time.  
 The subjective symptoms  of pruritus and sleep loss (2 items) are assessed by [CONTACT_81268] a 10 -cm visual analog scale . The symptoms (itch and sleeplessness) are 
recorded by [CONTACT_81269] a visual analogue scale, where [ADDRESS_88520] 3 days.  
The maximum possible SCORAD score calculated b ased on the above 3 aspects is 103. The 
higher scores indicate poorer or more severe condition (Stalder and Taïeb  1993; Oranje et al. 
2007; Schram et al. 2012). The recall period is present time for extent and intensity and average 
for the last 3 days  or nights for subjective symptoms of AD.  
8.1.6.  Modified Total Lesion Symptom Scale   
The Modified Total Lesion Symptom Scale  is an investigator -reported scale  that combines the 
evaluation of  hand eczema ( HE) lesion severity (erythema, edema, desquamation, fissures, 
hyperkeratosis  or lichenification, and vesicles) with the intensity of pruritus  or pain (Bissonnette 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
54 et al. 2010) to assess the severity of symptoms. This composite score assigns 0 (mild) to 3 
(severe) to each component, giving a maximum disease severity of 21. The recall period for this 
scale is the present time. While no validation of this score has been published, it has been used as 
a secondary endpoint in studies investigating alitretinoin in HE (Ruzicka et al. 2008; Fowler et 
al. 2014), and as a primary outcome measure in recent Phase 2 studies of dupi[INVESTIGATOR_81220] (N CT03861455; [STUDY_ID_REMOVED]).  
8.1.7.  Pruritus NRS   
The Pruritus Numeric Rating Scale ( NRS ) is a participant -reported , single -item, daily,  11-point 
scale . The Pruritus NRS is  used by [CONTACT_81270] 24 
hours with 0 indicating “No itch” and 10 indicating “Worst itch imaginable.” Assessments will 
be recorded daily by [CONTACT_2299] . The minimal clinically important change is 3 points. 
(Yosipovitch et al. 2019 , 2021 ).  
Participants will record the pruritus assessments daily using an electronic diary at home. As 
indicated in the SoA (Section 1.3), initial elect ronic diary entries for Pruritus NRS should be 
completed a minimum of [ADDRESS_88521] night. The Sleep -Loss Scale  is rated based 
on a 5 -point Likert scale (0 [not at all] to 4 [unable to sleep at all]) . Assessment will be recorded 
daily by [CONTACT_17071] . The minimal clinically important change is 3 points. (Yosipovitch et al . 
2021) .  
Participants will record the pruritus assessments daily using an electronic diary at home. As 
indicated in the SoA ( Section 1.3), initial electronic diary entries for Sleep -Loss  Scale  should be 
completed a minimum of 4 of 7 days before baseline .  
8.1.9.  Skin Pain Numeric Rating Scale (Skin Pain NRS)   
The Skin Pain NRS is a participant -reported , 11-point horizontal scale anchored at 0 and 10, with 
0 representing “no pain” and 10 representing “worst pain imaginable.” Overall severity of a 
participant’s skin pain is indicated by [CONTACT_80210] 24 h ours (Newton et al. 2019; Silverberg et al. 2021). Assessment will be 
recorded daily by [CONTACT_2299].  
8.1.10.  Dermatology  Life Quality Index/Children’s Dermatology Life Quality Index 
(DLQI/ cDLQI )  
The DLQI is a simple, participant -reported , 10-item, QoL questionnaire in adults that covers 6 
domains (symptoms and feelings, daily activities, leisure, work and school, personal 
relationships, and treatment ). The recall period of this scale is over the “last week.” Response 
categories include “not at all,” “a little”, “a lot,” and “very much,” with corres ponding scores of 
0, 1, 2, and 3, respectively, and unanswered (or “not relevant”) responses scored as 0. Scores 
range from [ADDRESS_88522] on a  participant’s HRQoL (Hongbo et al. 2005), and a 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
55 4-point change from baseline is considered as the minimal clinically important difference 
threshold (Khilji et al. 2002; Basra et al. 2015).  
Participants <16 years at baseline will complete the cDLQI  and sh ould continue to complete the 
cDLQI  for the duration of the study.  
8.1.11.  Atopic Dermatitis Control Tool (ADCT)   
The Atopic Dermatitis Control Tool  is a patient -reported, simple, brief t ool for adults and 
adolescents  that evaluates [ADDRESS_88523] week : 
overall severity of symptoms, days with intense epi[INVESTIGATOR_81221], intensity of bother, problem 
with sleep, impact on daily activities, and impact  on mood or emotions. Each of the 6 Atopic 
Dermatitis Control Tool  items has a score range from 0 (no problem) to 4 (worst), rating the 
severity of each concept; the total score ranges from 0 to 24, which is the summation of the 
responses to all the items. A score of ≥7 points was derived as the threshold to identify 
participants  “not in control .” The threshold for meaningful within -person change was estimated 
to be 5 points (Simpson et al . 2019; Pariser et al . 2020).  
8.1.12.  Participant -Reported Satisfaction  Question   
The question on participant satisfaction asks “ How satisfied are you with this treatment’s ability 
to treat your skin condition?” The response options range from 1 (not satisfied) to 5 (completely 
satisfied).  
8.1.13.  Fitzpatrick Skin Phototype Asse ssment   
The Fitzpatrick Scale is a clinician -rated scale and is based on a participant’s cutaneous reaction 
to sun exposure and baseline skin pi[INVESTIGATOR_371]. Fitzpatrick skin photot ypes range from I to VI, 
with a score of I indicating “always burns, does not tan, white skin tone” and a score of VI 
indicating “never burns, tans very easily, skin color black” (High et al . 2012). Investigators will 
follow the descriptive terms included in this protocol when recording the Fitzpatrick skin 
phototype . The sun sensitivity measure will represent the Fitzpatrick Scale score for each 
participant. The recall period for this scale is the present time.  
8.1.14.  Work Productivity and Activity Impairment Questionnaire –Atopic Dermatitis 
(WPAI -AD)  
The Work Productivity and Activity Impairment Questionnaire –Atopic Dermatitis  is a 
participant -reported , 6-item questionnaire that recor ds impairment due to AD over the past 7 
days in adolescents and  adults. The Work Productivity and Activity Impairment Questionnaire –
Atopic Dermatitis  consists of 6 items grouped into 4 domains: absenteeism (work time missed), 
presenteeism (impairment at wo rk or reduced on the job effectiveness), work productivity loss 
(overall work impairment  or absenteeism plus presenteeism), and activity impairment. 
Absenteeism, presentism, and work productivity will only be reported by [CONTACT_81271] (w orking for pay) at the time of the scale completion. The recall period for the scale is 
over the past 7 days. Scores are calculated as impairment percentages (Reilly et al. 1993), with 
higher scores indicating greater impairment and less productivity .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
56 8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
The routine safety assessments include physical examinations, clinical safety laboratory t ests 
(including hematology and chemistry), and collection of vital signs and spontaneously reported 
AEs. The study design includes a Post -treatment  Follow -Up Period with at least 1 study visit for 
safety assessments.  
8.2.1.  Clinical Safety Laboratory Tests   
● See Appendix [ADDRESS_88524] of clinical laboratory tests to be performed and the 
SoA for the timing and frequency.  
● Local anesthetics   
o Use of local anesthetics , for example , Eutectic Mixture of Local Anesthetics 
(EMLA ) cream , consistent with local prescribing information are permitted 
during the study visit to ease discomfort associated with venipunctures.  
● The investigator must review the laboratory results , document this review, and 
consider whether or not  any clinically relevant changes occurring during the study 
constitute as an AE . The laboratory results must be retained with source 
documents unless a Source Documen t Agreement or comparable document cite s 
an electronic location that accommodates the expected retention duration. 
Clinically significant abnormal laboratory findings are those which are not 
associated with the underlying disease, unless judged by [CONTACT_81272] d for the participant ’s condition.  
● All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within [ADDRESS_88525] dose of study 
intervention should be repeated until the values return to n ormal or baseline or are 
no longer considered clinically significant by [CONTACT_10982].  
○ If such values do not return to normal  or baseline within a period of time 
judged reasonable by [CONTACT_093], the etiology should be identifi ed and 
the sponsor notified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2, must 
be conducted in accordance with the SoA , standard collection requirements , 
and laboratory manual . 
● If laboratory values from non -protocol -specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant management or are considered clinically significant by [CONTACT_1275] , for example , SAE or AE or dose modification, then  report the 
information as an AE .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
57 8.2.2.  Hepatic Safety   
Close hepatic monitoringa 
Laboratory tests (Appendix 6), including alanine aminotransferase  (ALT), aspartate 
aminotransferase  (AST ), alkaline phosphatase  (ALP ), total bilirubin  (TBL ), direct bilirubin , 
gamma -glutamyl  transferase , and creatine kinase , should be repeated within 48 to 72  hours to 
confirm the abnormality and to determine if it is increasing or decreasing, if 1 or more of these 
conditions occur:  
If a participant with baseline results 
of... develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN , except for patients with Gilbert’s 
syndrome  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline , except for patients with Gilbert’s 
syndrome  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotr ansferase; 
TBL = total bilirubin; ULN = upper limit of normal.  
a All ULN values should be age adjusted (AAULN) for participants <18 years of age.  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes  of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this evaluation should include physical 
examination and a thorough medical history, including symptoms, recent illness es (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, and history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant ’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once e very 1 to 2 weeks, if the 
participant ’s clinical condition and lab results stabilize.  Monitoring of ALT, AST, ALP, and TBL 
should continue until levels normalize or return to approximate baseline levels. For participants 
<18 years of age, special care shou ld be taken to minimize the volume of blood taken during 
hepatic monitoring.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
58 Comprehensive hepatic evaluationa 
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs  or symptomsb, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs  or symptomsb, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal.  
a All ULN values should be age adjusted (AAULN) for participants <18 years of age.  
b Hepatic si gns or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, and 
rash. 
For Adult Participants (≥18 years old)  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalized ratio ; 
tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis ; and an abdominal imaging 
study , for example, ultrasound or computed tomography  scan.  
Based on the patient ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson ’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstanc es and the investigator ’s assessment of the 
participant ’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrogra de cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
For Adolescent Participants ( <18 years old)  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalized ratio  
and direct bilirubin, if total bilirubin was elevated.  
Based on the participant ’s age, medical history , and initial results, further testing should be 
considered in consultation with the Lilly -designated medica l monitor, including tests for viral 
hepatitis A, B, C, E; autoimmune hepatitis; and/or an abdominal imaging study , for example, 
ultrasound, MRI, or computed tomography  scan. Consider additional tests, based on the medical 
history and clinical pi[INVESTIGATOR_1103], including tests for hepatitis D virus , cytomegalovirus , Epstein -Barr 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
59 virus , acetaminophen levels, acetaminophen protein adducts, urine toxicology screen, Wilson ’s 
disease,  blood alcohol levels, urinary ethyl glucuronide, and blood phosphatidylethanol. Special 
care should be taken to prioritize more pertinent blood tests and minimize the volume of blood 
taken during hepatic evaluation. Based on the circumstances and the inve stigator ’s assessment of 
the participant ’s clinical condition, the investigator should consider referring the participant for a 
pediatric hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatography , endoscopic retrograde ch olangiopancreatography , cardiac 
echocardiogram, or a liver biopsy as deemed appropriate for the clinical condition and 
participant ’s age.   
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:a 
1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests , if baseline 
ALT < 1.5x ULN  
➢ In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests  
2. Elevated TBL to ≥2x ULN , if baseline TBL <1.5x ULN (except for cases of known 
Gilbert ’s syndrome)  
➢ In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests , if baseline 
ALP <1.5x ULN  
➢ In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood t ests 
4. Hepatic event considered to be a SAE  
5. Discontinuation of study drug due to a hepatic event  
NOTE : the interval between the [ADDRESS_88526] values should be age adjusted (AAULN) for participants <18 years o f age.  
8.2.3.  Hepatitis B Testing and Monitoring   
As specified in the SoA ( Section 1.3), initial testing for HBV infection includes HBsAg and 
hepatitis B core anti body  (HBcAb ). 
● If HBsAg is positive, the participant is excluded.  
● If HBsAg is negative and HBcAb  is negative, the participant is not excluded.  
● If HBsAg is negative and HBcAb  is positive, further testing for HBV DNA is 
required.  
○ If the screening HBV DNA is positive, the participant is excluded.  
○ If the screening HBV DNA is negative, the participant is not excluded. Repeat 
testing for HBV DNA is  required at least every 3 months during the study  as 
described in the SoA . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
60 Management of enrolled participants with detectable HBV DNA during the study  
If HBV DNA is detected, study intervention will be temporarily withheld or permanently 
discontinued, as described in Sections  7.1.2  and 7, and the participant should be referred for  
appropriate follow -up medical care. 
8.2.4.  Hepatitis C Testing   
As specified in the SoA ( Section 1.3), initial testing for HCV infection includes testing for 
antibodies to HCV ( anti-HCV ). 
● If anti -HCV is positive, a test for circulating HCV RNA is required.  
● If HCV RNA test is negative, the participant is not excluded.  
● If HCV RNA test is positive, the pa rticipant is excluded (see Section 5.2). 
Participants who have had HCV infection and have been successfully treated, defined as a 
sustained virologic  response (HCV RNA by [CONTACT_81273] 24 
weeks following treatment completion) , are not excluded on the basis of HCV as long as HCV 
RNA test is negative at screening.  
If HCV RNA is detected during the study, the study intervention will be discontinued 
(Section  7), and the participant should receive appropriate follow -up medical care.  
8.3. Adverse Events , Serious Advers e Events , and Product Complaints   
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs , and  
 PCs. 
These events will be reported by [CONTACT_2299] , or when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative.  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain re sponsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention  or study (see Section 7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits  or contacts. All SAEs and AEs of special interest , as defined in Section 8.3.[ADDRESS_88527] to follow -up (as defined in Section 7.3). For PCs, the investigator is responsible for 
ensuring that follow -up includes any supplemental investigations as indicated to elucidate nature  
and/or causality. Further information on follow -up procedures is provided in Section, 10.3, 
Appendix  3.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
61 8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanis m for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Adverse Event  
AE Signing of 
the ICF  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing of 
the ICF  Start of 
intervention  Within 24 h ours of 
awareness  SAE paper form  SAE  paper 
form  
SAE  and SAE 
updates  – after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 h ours of 
awareness  SAE paper form  SAE paper 
form  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  At least [ADDRESS_88528] dose 
of study 
intervention  Within 24 h ours (see 
Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88529] led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed and dated by 
[CONTACT_093]  N/A 
PC, if 
investigator 
becomes aware  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event; ICF = informed consent form; N/A = not applicable; PC = product complaint 
SAE = serious adverse event.  
a Serious adverse event  should not be reported unless the investigator deems them to be possibly related to study 
treatment  or study participation . 
8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male participants who receive study 
intervention . 
● After learnin g of a pregnancy in the female partner of a study participant, the 
investigator  
o will request  a consent  or assent  to release information  from the pregnant 
female partner directly, and 
o within [ADDRESS_88530] pregn ancy 
information on the appropriate form and submit it to the sponsor.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
63 The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the f ollow -up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age,  fetal status (presence or absence of 
anomalies) , or indication for the procedure.  
Female pa rticipants who become pregnant  
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the spo nsor within 24  
hours of learning of a participant ’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate , 
and the information will b e forwarded to the sponsor. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless of gestational age,  fetal 
status (presence or absence of anomal ies), or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion , occurring at <20 weeks gestational age , or still birth , 
occurring at ≥20 weeks gestational age , is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention  by [CONTACT_79982]  8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, they may learn of an SAE through 
spontaneous reporting.  
● Any female participant who becomes pregnant while participating in the study 
will discontinue study intervention . If the participant is discontinued from the 
study, follow the standard discontinuation process and continue directly to the 
follow -up phase. The follow -up on the pregnancy outcome should continue 
independent of intervention or study discontinuation.  
Prior to continuation of study intervention followi ng pregnancy, the following must occur:  
● The sponsor and the relevant institutional review board/independent ethics committee 
(IRB/IEC ) give written approval.  
● The participant gives signed informed consent  (or assent , as applicable) . 
● The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and the participant’s offspring.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88531] ( AESI ): 
 conjunctivitis  
 herpes infection or zoster, and  
 parasitic infection or an infection -related to an intracellular pathogen.  
If these AESIs are reported, sites will be prompted t o collect additional data. Participant records 
must include any follow -up information regarding these AESI. Study  intervention should be 
discontinued if an AE is deemed persistent and if continuation of  study intervention would not be 
in the best interest of the participant . Discuss discontinuation of study intervention with the 
sponsor or designee prior to implementation.  
[IP_ADDRESS].  Infections, Including Serious Infections and Opportunistic Infections   
Completion of the Infection CRF page is required for each infection reported as an AE or SAE. 
The sponsor will identify infections considered to be opportunistic based on the article by 
[CONTACT_81274]. ( 2015) ( Section 10.9, Appendi x 9). 
8.3.4.  Facial Dermatitis   
Completion of the facial dermatiti s follow -up CRF page is required for each facial dermatitis  
event reported as an AE or SAE.  
8.3.5.  Hypersensitivity   
Many drugs, including oral agents and biologic agents, carry the risk  of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study parti cipants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as described in Section 10.2.1 . Laboratory results are provided to the sponsor via the 
central laboratory . 
8.3.6.  Injection Site Reactions   
Symptoms and signs of a local injection site reaction may include erythema, induration, pain, 
pruritus, and edema.   
If an injection site reaction  is reported by a participant or site staff, the injection site reaction  
CRF will be used to capture additional information about this reaction , for example, injection  site 
pain, degree and area of erythema, induration, pruritis , and edema.  
8.4. Pharmacokinetics   
At the visits and times specified in the SoA, venous blood samples will be collected and stored 
for potential analysis of serum concentrations of leb rikizumab .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
65 Samples will be stored at a facility designated by [CONTACT_81275] a later date  
at a laboratory approved by [CONTACT_4682] a validated enzyme -linked immunosorbent assay 
method.  
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456]. 
The actual data and time (24 -hour clock time) of each sample and the most recent lebri kizumab 
dose prior to PK blood draw must be recorded.  
Sample retention is described in Section 10.1.[ADDRESS_88532] 
participant visit for the study. During this time, samples remaining after the bioanalysis may be 
used for exploratory analyses such as bioanalytical assay validation or cross -validation exercises.  
8.5. Pharmacodynamics   
Pharmacodynamic parameters are not evaluated in this study.  
8.6. Genetics   
A blood sample for DNA isolation wil l be collected from participants.  
See Appendix 10.5 for Information regarding genetic research  and Section  10.1.11  for details 
about  sample retention and c ustody .  
8.7. Biomarkers   
 Serum samples will be collected to discern responder variability within the study and to 
track response variability to lebrikizumab. Biomarkers will include but not limited to 
 
 Samples will be collected according to the 
schedule described in the SoA and as detailed in laboratory manual provided separately 
to sites . 
 The sponsor  may store samples according to Section 10.1.11 . Additionally, with 
participants’ consent, samples may be used for further research by [CONTACT_81276], the development of related or new treatments, or research methods.  
8.8. Immunogenicity Assessments   
At the visits and times specified in the SoA, venous blood samples will be collected for the 
purpose of determining  antibody production against lebrikizumab. To aid interpret ation  of these  
results, a blood sample for PK analysis will be collected at the same time points.   
All samples for immunogenic ity should be taken pre dose when applicable and possible. 
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456] . 
The actual date and time (24 -hour clock time) of each sample collection will be recorded.  
Immunogenicit y samples will be stored at a facility designated by [CONTACT_81277] a validated assay designed to detect ADAs in the presence  of lebrikizumab  at a 
laboratory designated by [CONTACT_456] . Samples may also be used for the development and control 
of an immunogenicity assay.  
Approved on 27 Apr 2023 GMT
CCI
CONFIDENTIAL  J2T-MC-KGBO (a) 
66 Treatment -emergent ADA s are defined in Section [IP_ADDRESS] . 
Sample retention is described in  Section 10.1.11 . 
8.9. Health Economic s  
Health economics and/or medical resource utilization will not be collected as part of  this study . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88533] 75% improvement  in 
baseline EASI at Week 16 in participants with moderate -to-severe AD who were previously 
treated with  dupi[INVESTIGATOR_81222]. There is no hypothesis testing plan ned nor inference statistical analysis 
planned .  
9.2. Analyses  Sets  
Participant Analysis Set  Description  
ITT population  All enrolled  participants. Participants will be included in the analyses 
according to the planned intervention.  
Safety population  All participants who are exposed to study intervention.  
 Abbreviation: ITT = intent -to-treat.  
9.3. Statistical Analyses   
9.3.1.  General Considerations   
Statistical analysis of this study will be the responsibility of Lilly or its designee. A detailed SAP 
describing the statistical methodologies will be developed by [CONTACT_81278].  
Any change to the  data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be  described 
in the CSR. Additional exploratory analyses of the data will be conducted as deemed appropriate.  
All analyses  will be  descriptive . Frequencies, percentages , and 90% CI  for percentages  will be 
reported  for discrete efficacy endpoints. Mean, standard deviation, minimum, Q1, median,  Q3, 
maximum , and the number of parti cipants will be reported for continuous efficacy endpoint s. 
AEs, discontinuation, and other categorical safety data will be summarized using frequencies and 
perce ntage. Continuous vital signs, body weight, and other continuous safety variables including 
laboratory variables will be summarized descriptively as well.  
9.3.2.  Primary Endpoint (s)/Estimand(s)  Analysis   
The primary endpoint is EASI -[ADDRESS_88534] is:  What is the intervention  effect in percentage of participants achieving EASI -75 after 
16 weeks of lebrikizumab 250  mg intervention in participants with moderate -to-severe AD who 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88535] an intercurrent event such as initiating rescue 
medication or per manently discontinuing treatment . All observed data will be included in 
summary statistics. All summary statistics will be based on observed data.  
9.3.3.  Secondary Endpoint (s)/Estimand(s)  Analysis   
Secondary endpoints outlined in the objective will be analyzed similarly to the primary endpoint 
of the primary estimand, that is,  using all observed data . For categorical endpo ints related to 
reaching a threshold , analyses will be evaluated in  participants who satisfy baseline minimum 
value (for xx -point improvement, baseline value need to be ≥xx) in intent -to-treat set. 
9.3.4.  Exploratory Endpoint (s) Analysis   
Other exploratory endpoints specified in Section [ADDRESS_88536] 1 TEAE will be summarized using MedDRA (Medical 
Dictionary for Regulator y Activities) for each system organ class (or a body system) and each 
preferred term. SAEs and AEs that lead to discontinuation of study intervention will also be 
summarized.  
All clinical laboratory results will be descriptively summarized. Individual resu lts that are 
outside of normal reference ranges will be flagged in data listings. Quantitative clinical 
hematology, chemistry, and urinalysis variables obtained at the baseline to postbaseline visits 
will be summarized as changes from baseline . Categorical  variables, including the incidence of 
abnormal values and incidence of AEs of special interest, will be summarized by [CONTACT_81279]. Shift tables might  be presented for 
selected measures.  
Observed val ues and changes from baseline (predose or screening if missing) for vital signs and 
physical characteristics will be descriptively summarized by [CONTACT_7206].  
The SAP may include additional safety analy ses if needed.  
9.3.6.  Other Analyses   
[IP_ADDRESS].  Subgroup Analyses   
Subgroup (subpopulation)  analyses of the primary endpoint and selected  secondary endpoints at 
Weeks 16 and 24 may be conducted for  intended -to-treat set. Subgroup to be evaluated may 
include  baseline severity, sex, age, race, and reasons for  discontinuation for previous ly treated 
with dupi[INVESTIGATOR_12458] .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
69 Definitions for the levels of the subgroup variables and any additional  subgroup analyses will be 
defined in the SAP i f applicable. All analyses will be  descriptive and  should be treated as 
exploratory .  
[IP_ADDRESS].  Biomarker Analyses   
Biomarker analys es will be described in the SAP.  
[IP_ADDRESS].  Pharmacokinetic Analyses   
PK samples will be stored and may be later assessed. If assessed,  PK analyses may be described 
in the SAP.  
[IP_ADDRESS].  Immunogenicity Assessments   
Immunogenicity samples will be stored and may be later assessed. If assessed, the frequency and 
percentage of participants with pre existing  anti-drug antibody ( ADA ) and who are treatment -
emergent ADA positive (TE ADA+) to lebrikizumab  will be tabulated.  
Treatment -emergent ADAs are defined as participants  
 with a 2 -fold (1 dilution) increase in titer than the minimum required dilution if no ADAs 
were dete cted at baseline (treatment -induced ADA), or  
 with a 4 -fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).  
The distribution of titers and frequency of neutralizing antibodies (if assessed) f or TE ADA+ 
participant s may also be tabulated.  
The relationship between the presence of ADA  and PK parameters, efficacy response , or safety 
to lebrikizumab  may also be assessed.  
Additional details may be provided in the SAP.  
9.4. Interim Analys is  
One interim analysis (primary lock) will be conducted after all enrolled participants have been 
evaluated at Week 16 or discontinue d prior to Week 16. This interim database lock  will include 
all efficacy and safety data collected by [CONTACT_81280]. Due to the open -label and descriptive 
nature of this study, this is no unblind nor alpha adjustment.  
Additional analyses and snapshots of study data may be performed to fulfill the ne ed for 
regulatory interactions or publication purposes.  
The SAP will describe the planned interim analyses in greater detail . 
9.5. Sample Size Determination   
Based on available data, the anticipated EASI -75 response rate is approximately 50%. A  total 
sample size of 120 enrolled participants  will provide >95% probability  that the 2-sided  90% CI 
of the EASI -[ADDRESS_88537] 10%. 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
70 With a total sample size N  = 120, example point estimate of  response rates and corresponding 2 -
sided 90% CI based on Wilson (Score) method  are summarized in the table below . The values 
are provided as reference rather than a basis of any decision criteria . 
Estimated 90% CI with Sample Siz e of 120 Participants  
Example  Point Estimates  Lower Bound of 90% CI  Upper Bound of 90% CI  
40% 32.9%  47.5%  
45% 37.7%  52.5%  
50% 42.6%  57.4%  
55% 47.5%  62.3%  
60% 52.5%  67.1%  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
71 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
● This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines includi ng 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences International Ethical Guidelines  
○ Applicable ICH GCP Guidelines  
○ International Organization for Standardization [ZIP_CODE]  
○ Applicable laws and regulations  
● The p rotocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by [CONTACT_10998]/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants . 
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annua lly or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct fo r participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations , ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations  
● Investig ator sites are compensated for participation in the study  as detailed in the 
clinical trial agreement . 
10.1.2.  Financial Disclosure   
Investigators and sub -investigators will provide the s ponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
72 certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing  information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process   
● The investigator or the investigator’s  representative will explain the nature of the 
study , including the risks and benefits,  to the participant , or the participant’s  
legally authorized representative , and answer all  questions regarding the study.  
● Participants must be informed that their par ticipation is voluntary. Participants , or 
their legally authorized representative s, will be required to sign a statement of 
informed consent that meets the requirements of 21 Code of Federal Regulations  
50, local regulations, ICH guidelines, privacy and da ta protection requirements, 
where applicable, and the I RB/IEC or study center.  
● For adult participants, the  medical record must include a statement that written 
informed consent was obtained before the participant was enter ed in the study and 
the date the  written consent was obtained. The authorized person obtaining the 
informed consent must also sign the ICF.  
● For adolescent participants, the medical record must include a statement that legally 
acceptable representative or parent(s) consent and child/ado lescent assent (if deemed 
appropriate by [CONTACT_81281]) was obtained before the participant was enrolled in 
the study and the date the written consent was obtained. The medical record should also 
describe how the clinical investigator determined that  the person signing the ICF was the 
participant’s legally acceptable representative or parent(s). The acceptable person 
obtaining the informed consent must also sign the ICF.  Adolescent participants who 
become 18 years of age while on study, will need to r e-consent.   
● Participants (or their legally acceptable representative, parent(s), or legal 
guardian ) must be reconsented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must be provided to the participant , or the participant’s 
legally authorized representati ve, and is kept on file . 
Participants who are rescreened are required to sign a new ICF.  
10.1.4.  Data Protection   
● Partic ipants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records , datasets , or tissue samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant ide ntifiable will not be transferred.  
● The participant must be informed that the participant’s  personal study -related data 
will be used by [CONTACT_10999]. The 
level of disclosure must also b e explained to the participant  who will be required 
to give consent for their data to be used as described in the informed consent .  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
73 ● The participant must be informed that their medical records may be examined by 
[CONTACT_81282], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
● The sponsor has processes in place to ensure data protection, information security , 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
10.1.5.  Dissemination of Clinical Study Data   
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].   
Data  
The sponsor provides access to all individual participant data collected during the trial, after 
anonymization, with the ex ception of PK or genetic data.  Data are available to request [ADDRESS_88538], see the instructions provided at www.vivli .org. 
10.1.6.  Data Quality Ass urance   
● All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electronically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in  the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents.  
● Quality tolerance limits (QTLs) will be pre -defined to identify sys tematic issues 
that can impact participant safety and/or reliability of study results. These pre -
defined parameters will be monitored during the study and important excursions  
from the QTLs and remedial actions taken will be summarized in the clinical 
study report . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
74 ● Monitoring details describing strategy ( for example , risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and 
analytical risk -based monitori ng), methods, responsibilities and requirements, 
including  handling of noncompliance issues and monitoring techniques are 
provided in the Monitoring Plan.  
● The sponsor or designee is responsible for the data management of this study 
includin g quality checking of the data.  
● The sponsor assumes accountability for  actions delegated to other individuals ( for 
example , contract research organizations ). 
● Study monitors will perform ongoing source data verification to confirm that data 
transcribed into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regu latory requirements.  
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_81283] a 
longer retention period. No records may be destroyed during the retention period 
without the written approval of the sponsor. No records may be transferred to 
another location or party without written notification to the sponsor . 
● In addition, sponsor  or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by [CONTACT_81284], and/or regulatory agencies at 
any time. Investigators wi ll be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An EDC will be used in this study for the collection of  CRF data. The investigator maintains a 
separate source for the data entered by [CONTACT_81285] -provided 
EDC system. The investigator is responsible for the identification of any data to be considered 
source and for the confir mation that data reported are accurate and complete by [CONTACT_11003] . 
Additionally, the skin  assessment using the Fitzpatrick Skin Type scale  will be collected by [CONTACT_81286] a paper source document and will be transcribed by [CONTACT_81287] . 
Additionally, electronic clinical outcomes assessment ( COA ) data ( participant -focused outcome 
instrument ) will be directly recorded by [CONTACT_2299] /investigator site personnel , into an 
instrument ( for example, handheld  smart phone or tablet ). The electronic COA  data will serve as 
the source documentation , and the investigator does not maintain a separate written or electronic 
record of these data.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
75 Data collected via the sponsor -provided data capture  system (s) will be  stored at third parties . The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system (s). Prior to decommissioning, the investigator will receive or access 
an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports  will be provided to the investigator for review 
and retention. Data will  subsequently be transferred from the central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global PC 
management system.  
10.1.7.  Source Documents   
● Source  documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported  on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medi cal records must be 
available.  
● Definition of what constitutes source data can be found in Section  10.1.[ADDRESS_88539] site open  and will  be the study start date.  
Study or Site Termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study  site closure visi t has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_52013]:  
For study termination:  
 Discontinuation of further study intervention development  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
76 For site termination:  
● Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health  authorities, the sponsor ’s procedures, or GCP guidelines  
● Inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_093]  
● Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_81288]. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.9.  Publication Policy   
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.10.  Investigator Information   
Researchers wit h appropriate education, training, and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical trial.  
10.1.11.  Sample Retention   
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of lebrikizumab  or after  lebrikizumab  become(s) commercially available.   
Sample Type  Custodian  Retention Period after 
Last Participant Visit  
Biomarkers  Sponsor or Designee  7 years  
PK Sponsor or Designee  1 year 
Genetics  Sponsor or Designee  7 years  
Immunogenicity  Sponsor or Designee  7 years  
Abbreviation: PK = pharmacokinetics.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
77 10.2. Appendix 2: Clinical Laboratory Tests   
● The tests detailed in the table below will be performed by [CONTACT_2237] . 
● In circumstances where the sponso r approves local laboratory testing in lieu of 
central laboratory testing (in the table below), the local laboratory must be 
qualified in accordance with applicable local regulations.  
● Protocol -specific requirements for inclusion or exclusion of participa nts are 
detailed in Section  5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
● Investiga tors must document  their review of the laboratory safety results.  
Clinical Laboratory Tests  Comments  
Hematology  Assayed by [CONTACT_11007] -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration   
Absolute neutrophil count (calculation ) 
(definition – include segs and bands or segs, 
bands and other immature cells)    
Leukocytes (WBCs)    
Differential    
Percent and absolutes count of:    
   Neutrophils, segmented    
   Neutrophils, bands   
   Lymphocytes    
   Monocytes    
   Eosinophils    
   Basophils    
Platelets    
Cell morphology (RBCs and WBCs)    
    
Clinical Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Total bilirubin    
Direct bilirubin    
ALP    
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88540]    
GGT    
BUN    
Creatinine    
CK   
Uric acid    
Total protein    
Albumin    
Calcium    
Phosphorus    
LDH    
    
Hormones (female)    
Serum pregnancy  Assayed by [CONTACT_11007] -designated laboratory  
Urine pregnancy  Assayed and Evaluated locally  
    
HIV and Hepatitis Serology  Assayed by [CONTACT_11007] -designated laboratory  
HIV testing    
HCV testing:    
    HCV antibody    
    HCV RNA    
HBV testing:    
   HBV DNA  Performed only for participants who test positive for HBcAb 
   HBcAb    
   HBsAg    
   HBsAb   
    
Exploratory Biomarker s  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
  
Immunoglobulins  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
IgE (Serum)    
    
Genetics Sample  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
    
Exploratory Biomarker storage samples  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
Serum    
Approved on 27 Apr 2023 GMT
CCI
CONFIDENTIAL  J2T-MC-KGBO (a) 
79 Clinical Laboratory Tests  Comments  
  
Immunogenicity  (ADA ) samples  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to the investigative sites  
Anti-LY3650150 antibodies   
  
Pharmacokinetic Samples  – LY3650150  
concentration  Assayed by [CONTACT_11007] -designated laboratory  
Results will not be provided to  the investigative sites  
Abbreviations : ADA = anti -drug antibodies;  ALP = a lkaline phosphatase; ALT = alanine aminotransferase; 
AST  = aspartate aminotransferase; BUN  = blood urea nitrogen; CK = creatine kinase; GGT = Gamma -glutamyl 
transferase ; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B 
surface antigen; HBV  = hepatitis B virus; HCV = hepatitis C virus; HIV  = human immunodeficiency virus;  
IgE = immunoglobulin E; IL = interleukin; LDH = l actic dehydrogenase ; PK = pharmacokinetics ; RBC = red 
blood cells;  WBC = white blood cells . 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event   
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hyperse nsitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the t able, assuming the participant has been stabilized.  
Obtain follow -up pre dose samples at the next regularly scheduled laboratory sample collection , 
ideally prior to the next dose after the event , to assess post -event return -to-baseline values.  
Timing  Labora tory Testa 
Collect from 30 min utes to 4 h ours after the start of 
the event.  
● NOTE : The optimal collection time is from [ADDRESS_88541] only if not already collected on the same day as 
the event.  
● NOTE : If collecting, collect up to [ADDRESS_88542] the date and time when the samples are collected.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
80 Allowed additional testing for  participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
81 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
 The definitions and procedures detailed in this appendix are in accordance with 
International Organization for Standardization (ISO) [ZIP_CODE].  
 Both the inve stigator and the sponsor will comply with all local medical device reporting 
requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_88543] of 
sponsor medical devices.  
10.3.1.  Definition of AE   
AE Definition  
 An AE i s any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavo rable  and unintended sign 
(including an abnorma l laboratory finding), symptom, or disease  (new or exacerbated)  
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory finding) in study participants, users, or 
other persons, whether or not related to the investigational medical device. This 
definition includes events related to the in vestigational medical device or comparator 
and events related to the procedures involved except for events in users or other 
persons, which only include events related to investigational devices.  
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for ex ample , electrocardiogram , radiological scans, vital 
signs measurements), including those that worsen from baseline, considered clinically 
significant in the med ical and scientific judgment of the investigator ( that is , not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre existing  condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical  sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
82 AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose s should be re ported regardless of sequelae.  
 Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae r esulting from lack of efficacy 
will be reported as AE or SAE if they fulfil l the definition of an AE or SAE.  
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied,  unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure ( for example , endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur ( social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of pre existing  disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
 In general, hospi[INVESTIGATOR_51955] (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physicia n’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be 
considered serious.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
83  Hospi[INVESTIGATOR_5187] a pre existing  condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantia l disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental traum a (for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised by [CONTACT_81289] -threatening or result in death or hospi[INVESTIGATOR_51957]. These event s should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse.   
g. Resulted in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.   
10.3.3.  Definition of Product Complaints   
Product Complaint  
A PC is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness , or performance of a 
study intervention . When the ability to use the study intervention safely is impacted, 
the following are also PCs: 
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
84  PCs related to study inte rventions used in clinical trials are collected in order to ensure 
the safety of participants, monitor quality, and to facilitate process and product 
improvements.  
 Investigators will instruct participan ts to contact [CONTACT_11010] a PC or problem with the study inte rvention so that the situation can be assessed.  
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /PC information in the 
participant’s medical records , in accordance with the investigator’s normal clinical 
practice. AE/SAE information is reported on the appropriate CRF page and PC 
information is reported on the Product Complaint Form . 
NOTE : An event may meet the definition of both a PC and an AE/SAE. In such cases, 
it should be reported as both a PC and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the Product Complaint Form for PCs. 
 There may be instances when copi[INVESTIGATOR_51958] . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the  copi[INVESTIGATOR_51959] . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual s igns/symptoms) will be documented as the AE/SAE.   
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
85 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:   
 Mild:  A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
 Moderate:  A type of adverse event that is usually alleviate d with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of adverse event that interru pts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention . 
An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of  an event; and both AEs and SAEs can be 
assessed as severe.  
An event is defined as “serious ” when it meets at least one of the pre -defined  outcomes 
as described in the definition of an SAE, NOT when it is rated as severe .  
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship/  
 A “reasonable possibility ” of a relationship conveys that there a re facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of t he event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and h as provided an assessment of causality.  
 There may be situations in which an SAE has occurred,  and the investigator has 
minimal information to include in the initial report to Sponsor or designee . However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to Sponsor or designee . 
 The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send a SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
86  
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_52017]/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period,  the inv estigator will provide Sponsor or designee  with a copy of any 
post-mortem findi ngs including histopathology.  
10.3.5.  Reporting of SAEs   
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the medical monitor or the SAE coordinator . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in SAE form.   
10.3.6.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
 Prompt notification by [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities toward  the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor  has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will evaluate the reported SAEs, 
including confirmation of relatednes s and assessment of expectedness. The 
sponsor has processes for safety reports for identification, recording, and 
expedited reporting of suspected unexpected serious adverse reactions  
according to local regulatory requirements. The sponsor will comply with  
country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Boards (IRB)/Independent Ethics 
Committees (IEC) , and investigators.  
● An investigator who receives an investigator safety report descr ibing a SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the sponsor will review and then file it along with the IB will notify the 
IRB/IEC, if appropriate according to local requirements.   
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
87 10.4. Appendix 4: Contraceptiv e and Barrier Guidance   
10.4.1.  Definitions   
Women of child -bearing  potential (WOCBP)  
Females are considered WOCBP if they have had at least 1 cycle of menses.  
Any amount of spotting or bleeding should be considered menarche.  
Women not of child -bearing  potential (WNOCBP)  
Females are considered WNOCBP  if they  
 have a congenital anomaly such as Mullerian agenesis  
 are infertile due to surgical sterilization, or  
 are postmenopausal.  
Examples of surgical sterilization include total hysterectomy, bilateral salpi[INVESTIGATOR_8936] -oophorectomy, 
bilateral salpi[INVESTIGATOR_1656], or bilateral oophorectomy.  
Postmenopausal  
The p ostmenopausal state is defined as ≥[ADDRESS_88544].  
10.4.2.  Contraception Guidance   
Guidance for WOCBP  
This outlines the rules for WOCBP to ensure they do not become pregnant during the study.  
 
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship as their preferred and usual lifestyle:  
Must…  Must not…  
agree to either 
remain abstinent or 
stay in a same -sex 
relationship without 
sexual relationships 
with males   use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation  
 declare abstinence just for the duration of a trial, or  
 use the withdrawal method  
 
WOCBP , who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same -sex relationship as their preferred and usual lifestyle, must do the following:  
Topic  Condition  
Pregnancy testing  Have a negative serum test result at screening (or upon a participant 
that reaches menarche during the trial and is sexually active) followed 
by a negative urine result within 24 h ours prior to treatment exposure. 
See the protocol SoA for subsequent pregna ncy testing requirements.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88545] be used for the duration of the 
study.  
Examples of different for ms of contraception  
Methods  Examples  
Highly effective contraception 
(less than 1% failure rate)   female sterilization  
 combination oral contraceptive pi[INVESTIGATOR_4382]  
 progestin -only contraceptive pi[INVESTIGATOR_4382] (mini -pi[INVESTIGATOR_4382]) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198  pounds or 90 kg)  
 total abstinence  
 vasectomy , if only sexual partner  
 fallopi[INVESTIGATOR_31077] , if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913]  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide . 
NOTE : The barrier method must include use of a spermicide , that 
is, condom with spermicide, diaphragm with spermicide, and 
female condom with spermicide , to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (cal endar method, temperature 
method, combination of above 2, cervical mucus, 
symptothermal)  
 withdrawal  
 post coital douche , and  
 lactational amenorrhea  
 
Guidance for all men  
Males may participate in this trial.  
No male contraception is required except in compliance with specific local government study 
requirements.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
89 10.5. Appendix  5: Genetics   
Use/Analysis  of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolism, and excretion; mechanism of action of the 
drug; dise ase etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a sample will be collected 
for DNA analysis from consenting participants.  
● DNA samples will be used for research related to lebrikiz umab  or moderate -to-
severe AD and related diseases. They may also be used to develop tests  or assays 
including diagnostic tests related to lebrikizumab  and moderate -to-severe AD. 
Genetic research may consist of the analysis of one or more candidate genes o r 
the analysis of genetic markers throughout the genome or analysis of the entire 
genome  (as appropriate).  
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in the response to lebrikizumab  or study interventions of this 
class to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to prote ct confidentiality.  
● The samples will be retained while research on lebrikizumab continues but no 
longer than 15 years or other period as per local requirements.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
90 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
Hepatic Evaluation Testing  
See Section  8.2.[ADDRESS_88546] be qualified in accordance with applicable local regulations.  
Tests assayed by [CONTACT_11007] -designated central laboratory  
Hepatic Hematology Panel  Hepatitis A virus (HAV) testing:  
   Hemoglobin      HAV total antibody  
   Hematocrit      HAV IgM antibody  
   Erythrocytes (RBCs - red blood cells)  Hepatitis B virus (HBV) testing:  
   Leukocytes (WBCs - white blood cells)      Hepatitis B surface antigen (HBsAg)  
   Differential:      Hepatitis B surface antibody (anti -HBs)  
       Neutrophils, segmented      Hepatitis B core total antibody (anti -HBc)  
       Lymphocytes      Hepatitis B core IgM antibody  
       Monocytes      HBV DNA  a 
       Basophils  Hepatitis C virus (HCV) testing:  
       Eosinophils      HCV antibody  
   Platelets      HCV RNA  a 
   Cell morphology (RBC and WBC)  Hepatitis D virus (HDV) testing:  
Hepatic Clinical Chemistry Panel      HDV antibody  
   Total bilirubin  Hepatitis E virus (HEV) testing:  
   Direct bilirubin      HEV IgG antibody  
   Alkaline phosphatase (ALP)      HEV IgM antibody  
   Alanine aminotransferase (ALT)      HEV RNA a 
   Aspartate aminotransferase (AST)  Anti -nuclear antibody (ANA)  
   Gamma -glutamyl transferase (GGT)  Anti -smooth muscle antibody (ASMA) b 
   Creatine kinase (CK)  Anti -actin antibody c 
Hepatic Coagulation Panel  Immunoglobulin IgA (quantitative)  
   Prothrombin time, INR (PT -INR)  Immunoglobulin IgG (quantitative) 
Urine Chemistry  Immunoglobulin IgM (quantitative)  
   Drug screen  Epstein -Barr virus (EBV) testing:  
Haptoglobin      EBV antibody  
a Reflex/confirmation dependent on regulatory requirements, testing availability, or both . 
b Not required if anti -actin antibody is tested . 
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
91  
Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
Acetaminophen  Cytomegalovirus (CMV) testing:  
Acetaminophen protein adducts      CMV antibody  
Alkaline phosphatase isoenzymes      CMV DNA  a 
Ceruloplasmin  Herpes simplex virus (HSV) testing:  
Copper      HSV (Type 1 and 2) antibody  
Ethyl alcohol (EtOH)      HSV (Type 1 and 2) DNA  a 
Phosphatidylethanol (PEth)  Liver kidney microsomal type 1 (LKM -1) antibody  
Urine Chemistry  Microbiology  
    Ethyl glucuronide (EtG)  Culture:  
Epstein -Barr virus (EBV) testing:      Blood  
    EBV DNA  a     Urine  
 
a Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
 
 
 
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
92 10.7. Appendix 7: American Academy of Dermatology: Criteria for the 
Diagnosis and Assessment of Atopic Dermatitis   
Features to be considered in diagnosis of patients with AD:  
Essential Features —Must be present:  
 pruritus  
 eczema (acute, subacute,  chronic)  
o typi[INVESTIGATOR_73262] -specific  patterns*  
o chronic or relapsing  history  
*Patterns include : 
1) facial, neck, and extensor involvement in infants and children  
2) current or previous flexural lesions in any age group  
3) sparing of the groin and axillary regions  
Important Features —Seen in most cases, adding support to the diagnosis:  
 early age of  onset  
 atopy  
o personal and/or family  history  
o Immunoglobulin E  reactivity  
 xerosis  
 
Associated Features —These clinical associations help to suggest the diagnosis of AD 
but are too nonspecific to be used for defining or AD for research and epi[INVESTIGATOR_81223]:  
 atypi[INVESTIGATOR_73263] (e .g., facial pallor, white dermographism, delayed blanch  
response)  
 keratosis pi[INVESTIGATOR_22785]/pi[INVESTIGATOR_80166]/hyperlinear  palms/ichthyosis  
 ocular/periorbital  changes  
 other regional findings ( for example , perioral changes/periauricular  lesions)  
 perifollicular accentuation/lichenification/prurigo  lesions  
 
Exclusionary Features —It should be noted that a diagnosis of AD depends on 
excluding conditions, such as:  
 scabies  
 seborrheic  dermatitis  
 contact [CONTACT_81290] (irritant or  allergic)  
 ichthyoses  
 cutaneous T -cell lymphoma  
 psoriasis  
 photosensitivity  dermatoses  
 immune deficiency  diseases  
 erythroderma of other  causes  
Source: Eichenfield et al. Guidelines of care for the management of atopic dermatitis: section 1. 
Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol . 2014;70(2):338 -3351.   
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
93 10.8. Appendix 8: Medical Device Adverse Events ( AEs), Adverse Device 
Effec ts (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting   
Refer to Appendix 3 for defin itions and procedures for recording, evaluating, follow -up, and 
reporting of all events.  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
94 10.9. Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy   
This table lists examples of infections that may be considered opportunistic in the context of 
biologic therapy. This table is provided to aid the investigator in recognizing infections that may 
be considered opportunistic. This  list is not exhaustive. For data analysis, infections will be 
categorized by [CONTACT_81291]. (2015).  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
95 Examples of infections that may be considered opportunistic in the setting of biologic 
therapy  
Bacterial  
 Bartonellosis (disseminated disease only)  
 Campylobacteriosis (invasive disease only)  
 Legionellosis  
 Listeriosis (invasive disease only)  
 Nocardiosis  
 Tuberculosis  
 Non-tuberculous mycobacterial disease  
 Salmonellosis (invasive disease only)  
 Shigellosis (invasive disease only)  
 Vibriosis (invasive disease due to Vibrio vulnificus ) 
Viral  
 BK virus disease including polyomavirus -associated nephropathy  
 Cytomegalovirus disease  
 Hepatitis B virus reactivation  
 Hepatitis C virus progression  
 Herpes simplex (invasive disease only)  
 Herpes zoster (any form)  
 Post-transplant lymphoproliferative disorder (Epstein -Barr virus)  
 Progressive multifocal leukoencephalopathy (PML), John Cunningham (JC) vi rus  
Fungal  
 Aspergillosis (invasive disease only)  
 Blastomycosis  
 Candidiasis (invasive disease or oropharyngeal, esophageal. Not isolated lingual)  
 Coccidioidomycosis  
 Cryptococcosis  
 Histoplasmosis  
 Paracoccidioides infections  
 Penicilliosis  
 Pneumocystosis  
 Sporotrichosis  
 Other invasive molds: Mucormycosis (zygomycosis) ( Rhizopus , Mucor,  and Lichtheimia ), 
Scedosporium /Pseudallescheria boydii , Fusarium  
Parasitic  
 Leishmaniasis (visceral only)  
 Strongyloidiasis (hyperinfection syndrome or disseminated disease)  
 Microsporidiosis  
 Toxoplasmosis  
 Trypanosoma cruzi  infection (Chagas’ disease progression) (disseminated disease only)  
 Cryptosporidiosis (chronic disease only)  
Source: Based on Winthrop et al. (2015).  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
96 10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended  to be 
used only during specific time periods as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bo dies, and  any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required , for examp le, upon implementation and suspension of changes. All 
approvals and notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if nee ded. 
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely  in the study and maintaining the integrity of the study.  
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The followin g changes in study conduct will not be considered protocol deviations if written 
sponsor approval is given.   
Screening period guidance   
If the study screening window exceeds 30 days due to the exceptional circumstances, the 
participant would be considered a screen failure and may be rescreened if written sponsor 
approval is given.  
The screening procedures per the SoA in the protocol shoul d be followed (starting at Visit 1) to 
ensure participant eligibility by [CONTACT_23760] (Visit 2). Before rescreening, the participant 
must sign a new ICF and receive a new identification number through IWRS . 
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
97 Adjustments to visit windows  
Whenever possi ble and safe to do so, as determined by [CONTACT_093]’s discretion, participants 
should complete the usual S oA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidan ce and written 
approval from the sponsor.  This minimizes missing data and preserves the intended conduct of 
the study.  
This table describes the allowed adjustments to visit windows.  
Visit Number  Tolerance  
Weeks 2 -14 ±7 days  
Week 16  ±[ADDRESS_88547]-treatment safety follow -up ([ADDRESS_88548] dose)  ±[ADDRESS_88549] extended windows, subsequent dosing should be  a minimum 
of 7 days apart if the visit window is expanded due to exceptional circumstances.  
NOTE : Every e ffort should be made to enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff . 
Documentation  
Changes to study conduct will be documented  
Sites will identify and  document the details of how participants, visit window adjustments , and 
or rescreening were affected by [CONTACT_52022].  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
98 10.11.  Appendix 11: Abbreviations  and Definitions   
Term  Definition  
AD atopic dermatitis  
ADA  anti-drug antibody  
AE adverse event  
AESI  adverse event of special interest  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
AST aspartate amin otransferase  
BSA  body surface area  
CDLQI  Children’s Dermatology Life Quality Index  
CI confidence interval  
Companion 
diagnostic  An in vitro diagnostic device (assay or test) that provid es information that is essential 
for the safe and effective use of a corresponding therapeutic product  
complaint  A complaint is any written, electronic, or or al communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all  study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form; a printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial  participant.  
CRP  clinical re search physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician or other medical officer.  
CSR  Clinical study report  
DLQI  Dermatology Life Quality Inde x 
DMC  data monitoring committee . A data monitoring committee, or data monitoring board 
(DMB)  is a group of  independent scientists who are appointed to monitor the safety and 
scientific integrity of a human research intervention, and to make recommendations to 
the sponsor regarding the stoppi[INVESTIGATOR_31081] a study for efficacy, or for harms, or for futilit y. 
The composition of the committee is dependent upon the scientific skills and 
knowledge required for monit oring the particular study.  
Device deficiencies  equivalent  to product complaint  
EASI  Eczema Area and Severity Index  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
[ADDRESS_88550] been assigned to a treatment.  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable  representatives.  
FLG filaggrin  
GCP  Good Clinical Practice  
HBV  hepatitis B  virus  
HCV  hepatitis C virus  
HE hand eczema  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IGA Investigator’s Global Assessment  
IL interleukin  
IL-4R IL-4 receptor alpha  
IL-13R[ADDRESS_88551]  
informed consent  A process by [CONTACT_9444] a participant volu ntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the s tudy that are 
relevant to the participant’s decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consen t form . 
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceutic al form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products u sed for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
100 ITT intention to treat: The principle that asserts that the effect of a t reatment policy can be 
best assessed by [CONTACT_41445] a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocate d to a treatment grou p should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.  
IWRS  interactive web -response  system  
JAK Janus kinase  
LOR  loricrin  
NIMP  non-investigational medicinal product  
NRS  Pruritus Numeric Rating Scale  
participant  Equivalent to  CDISC term  “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PDE4  phosphodiesterase -4 
PD/PK pharmacodyna mics /pharmacokinetics  
PPS per-protocol set:  The set of data generated by [CONTACT_52023], according to the underlying scientifi c model.  
Q2W  once every [ADDRESS_88552] of determining if an individual meets minimum requirements to become part  of 
a pool of potential candidates for participation in a clinical study.  
SoA Schedule of Activities  
TARC thymus - and activation -regulated chemokine  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
101 TBL total bilirubin  
TCI topi[INVESTIGATOR_81224] -emergent adverse event:  An untoward medical occurrence that emerges 
during a define d treatment period, having been absent pretreatment, or worsens relative 
to the p retreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
Th1 T-helper type 1 
Th2 T-helper type 2  
Th17  T-helper type 17 
WOCBP  women of child -bearing potential  
  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
102 11. References   
Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. 
Eur Cytokine Netw . 2013;24(1):37 -44. https://doi.org/10.1684/ecn.2013.0333  
Basra MK, Salek MS, Camilleri L, et al.  Determining the minimal clinically important difference 
and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology . 
2015;230(1):27 -33. https://doi.org/10.1159/000365390  
Bieber T. Atopic dermatitis. N Engl J Med . 2008;358(14):1483 -1494. 
https://doi.org/10.1056/nejmra074081  
Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma 
Rep. 2009;9(4):291 -294. https://doi.org/10.1007/s11882 -009-0041 -2 
Bieber T.  Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and 
stratified medicine. Allergy.  2012;67(12):1475 -1482. https://doi.org/ 10.1111/all.[ZIP_CODE]  
Bieber T . Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis . Allergy . 
2020;75(1):54 -62. https://doi.org/10.1111/all.[ZIP_CODE]  
Bieber T, Straeter  B. Off-label prescriptions for atopic dermatitis in Europe . Eur J Aller Clin 
Immunol . 2015 ;70(1):6 -11. https://doi.org/10.1111/all.[ZIP_CODE]  
Bissonnette R, Diepgen T, Elsner P . Redefining treatment options in chronic hand eczema 
(CHE) . J Eur Acad  Dermatol  Venereol . 2010; 24(s3):1 -20.   https://doi.org/10.1111/j.[ADDRESS_88553], Mehregan DA.  A survey of self -reported skin disease in the elderly 
African -American population. Int J Dermatol . 2014; 54(9) :1034 -1038 . 
https://doi.org/10.1111/ijd.[ZIP_CODE]   
Choy DF, Hsu DK, Seshasayee D, et al. Comparative transcriptomic analyses of atopic 
dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol . 
2012;130(6):1335 -1343. https://doi.org/10.1016/j.jaci.2012.06.[ADDRESS_88554] allergy in the general population in 
different European regions . British J Dermatol . 2016 ;174:319-329. 
https://doi.org/10.1111/bjd.[ZIP_CODE]  
Eckert L, Gupta S, Amand C, et al.  The burden of atopic dermatitis in US adults: Health care 
resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad 
Dermatol . 2018;78(1):54 -61.e1.  https://doi.org/10.1016/j.jaad.2017.08.002  
Eckert L, Gupta S, Gadkari A, et al.  Burden of illness in adults with atopic dermatitis: Analysis 
of National Health and Wellness Survey data from [LOCATION_009], [LOCATION_013], Italy, Spain, and the 
[LOCATION_008]. J Am Acad Dermatol . 2019;81(1):187 -195. 
https://doi.org/10.1016/j.jaad.2019.03.037  
Esche C , de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. 
Curr Allergy Asthma Rep . 2004;4(4):276 -284. https://doi.org/10.1007/s11882 -004-0071 -8 
Faiz S, Giovannelli J, Podevin C et al. Effectiveness and safety of dupi[INVESTIGATOR_81225] a real -life French multicenter adult cohort. J Am Acad Dermatol . 
2019;81:143 -51. https://doi.org/10.1016/j.jaad.2019.02.053  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
103 Flohr C, Irv ine AD. Systemic therapi[INVESTIGATOR_81226]. 
J Allergy Clin Immunol . 2013;132(3):774 -774.e6. https://doi.org/10.1016/j.jaci.2013.03.016  
Fowler J, Graff O, Hamedani G . A phase 3, randomized, double -blind, placebo -controlle d study 
evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic 
hand eczema refractory to potent topi[INVESTIGATOR_81227] . J Drugs Dermatol . 
2014;13(10):1198 -204. 
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA.  Dupi[INVESTIGATOR_12458]: A review of its use in the 
treatment of  atopic  dermatitis.  Am Acad Dermatol . 2018;78(3):S28 -S36. 
https://doi.org/10.1016/j.jaad.2017.12.022  
Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL -12 and IL -13 in atopic 
dermatitis. J Alle rgy Clin Immunol . 1996;98(1):225 -231. https://doi.org/10.1016/s0091 -
6749(96)[ZIP_CODE] -4 
Hanifin JM, Thurston M, Omoto M, et al. EASI Evaluator Group. The eczema area and severity 
index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol . 2001; 10(1):11 -18. 
https://doi.org/10.1034/j.1600 -0625.2001.100102.x  
Harrop J, Chinn S, Verlato G, et al.  Eczema, atopy and allergen exposure in adults: a population -
based study . Clin Exper Aller . 2007; 37:526-535. https://doi.org/10.1111/j.1365 -
2222.2007.[ZIP_CODE].x  
He JQ, Chan -Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic  
diseases in at -risk children. Genes Immun . 2003;4(5):385 -389. 
Heibel H, Henddricks A, Foshee J, Shi V . Rosacea associated with dupi[INVESTIGATOR_81228] . J 
Dermatol Treat . 2021 ;32(1):114-116. https://doi.org/10.1080/09546634.2019.1624683  
High  WA, Tomasini CF, Argenziano G, Zalaudek I.  Basic principles of dermatology. In: 
Bolognia JL, Jorizzo JL, Schaffer JV, editor s. Dermatology (3rd ed.) . China: Elsevier ; 2012: pp. 
8. 
Hongbo Y, Thomas CL, Harrison MA, et al.  Translating the science of quality of life into 
practice: What do dermatology life quality index scores mean? J Invest Dermatol . 
2005;125(4):659 -664. https://doi.org/10.1111/j.[ADDRESS_88555] on S100/A11 to downregulate 
keratinocyte differentiation. J Invest Dermatol . 2008;128(9):2248 -2258. 
https://doi.org/10.1038/jid.2008.74  
Hua TC, Hwang CY, Chen YJ, et al. The natural course of early -onset atopic der matitis in 
Taiwan: a population -based cohort study. Br J Dermatol . 2014;170(1):130 -135. 
https://doi.org/10.1111/bjd.[ZIP_CODE]  
Hummelshoj T, Bodtger U, Datta P, et al. Association between an interleukin -13 promoter 
polymorphism and atopy. Eur J Immunogenet . 2003;30(5):355 -359. 
https://doi.org/10.1046/j.1365 -2370.2003.[ZIP_CODE].x  
Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 
7 years and the association with asthma. J Allergy Clin Immunol . 2004;113(5):925 -931. 
https://doi.org/10.1016/j.jaci.2004.01.778  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
104 Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional 
skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT -PCR. 
Clin Exp Allergy . 2003;33(12):17 17-1724. https://doi.org/10.1111/j.1365 -2222.2003.[ZIP_CODE].x  
Kiebert, G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in 
health -related quality of life. Int J Dermatol . 2002;41(3):151 -158. 
https://doi.org/10.1046/j.1365 -4362 .2002.[ZIP_CODE].x  
Kim BE, Leung DYM, Boguniewicz M, Howell MD. Loricrin and involucrin expression is 
down -regulated by [CONTACT_78443]2 cytokines through STAT -6. Clin Immunol . 2008;126(3):332 -337. 
https://doi.org/10.1016/j.clim.2007.11.006  
Khilji FA, Gonzalez M, Finlay AY.  Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol . 2002;147:25 -54. 
Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: 
consensus report of the European Task Force on Atopic Dermati tis. Dermatology . 
1997;195(1):10 -19. https://doi.org/10.1159/000245677  
La Grutta S, Richiusa P, Pi[INVESTIGATOR_81229] G, et al. CD4(+)IL -13(+) cells in peripheral blood well 
correlates with the severity of atopic dermatitis in children. Allergy . 2005;60(3):391 -395. 
https://doi.org/10.1111/j.1398 -9995.2005.[ZIP_CODE].x  
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet . 2020;396([ZIP_CODE]):345 -360. 
https://doi.org/10.1016/s0140 -6736(20)[ZIP_CODE] -1 
Marniquet M, Seneschal J, Darrigade A, et al.  Reasons for discontinuation of dupi[INVESTIGATOR_81230] . Br J Dermatol.  2022 . https://doi.org/10.1111/bjd.[ZIP_CODE]  
Miron Y, Miller P, Hughes C, et al.  Mechanistic insights into the antipruritic effects of 
lebrikizumab, an anti –IL-13 mAb . J Aller Clin Immun . 2022 . 1-11. 
https://doi.org/10.1016/j.jaci.2022.01.[ADDRESS_88556] dermatitis. J Allergy Clin Immunol . 2006;118(4):930 -937. 
https ://doi.org/10.1016/j.jaci.2006.07.015  
Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of 
newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep 
Outcomes . 2019;3(1):42. https://doi .org/10.1186/s41687 -019-0128 -z 
Novak N, Kruse S, Kraft S, et al. Dichotomic nature of atopic dermatitis reflected by [CONTACT_81292][INVESTIGATOR_81231] -4/interleukin -13 receptor gene: the dichotomy of extrinsic and intrinsic atopic 
dermatitis. J Invest Dermatol . 2002;119(4):870 -875. https://doi.org/10.1046/j.[ADDRESS_88557] -van der Spek FB. Practical issues on 
interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the 
three -item severity score. Br J Dermatol . 2007;157(4):645 -648. https://doi.org/10.1111/j.1365 -
2133.2007.[ZIP_CODE].x  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
105 Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient -perceived control of atopic 
dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). 
Curr Med Res Opin. 2020;36(3):367 -376. https://doi.org/10.1080/03007995.2019.[ADDRESS_88558]  CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol . 
2006;126(5):1043 -1051. https://doi.org/10.1038/sj.jid.5700085  
Reilly MC, Zbrozek AS, Dukes EM. The validity and reprod ucibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics . 1993;4(5):353 -365. 
https://doi.org/10.2165/00019053 -199304050 -[ZIP_CODE]  
Ruzicka T , Harsch M , Brown TC , et al.  Modified Total Lesion Symptom Score (mTLSS) . Br J 
Dermatol . 2008;158(4):808 -817. 
Sacotte R, Silverberg J . Epi[INVESTIGATOR_81232] . Clin Dermatology . 
2018 ;36:595-605. https://doi.org/10.1016/j.clindermatol.2018.05.007  
Saeki H, Tsunemi Y, Fujita H, et al.  Prevalence of atopic dermatitis determined by [CONTACT_81293] . J Dermatol . 2006;33(11):817 -819. 
https://doi.org/10.1111/j.1346 -8138.2006.[ZIP_CODE].x  
Safa G, Paumier V . Psoriasis induced by [CONTACT_24983][INVESTIGATOR_81228] . Clin Exp 
Dermatol . 2019;44(3):e49 -e50. https://doi.org/10.1111/ced.[ZIP_CODE]  
Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic 
eczema: responsiveness and minimal clinically important difference. Allergy . 2012;67(1):99 -
106. https://doi.org/10.1111/j.1398 -9995.2011.[ZIP_CODE].x  
Seegräber M, Srour J, Walter A, et al.  Dupi[INVESTIGATOR_81233].  Expert Rev 
Clin Pharmacol . 2018;11(5):467 -474. https://doi.org/10.1080/17512433.2018.1449642  
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of l ife in atopic 
dermatitis in US adults : A population -based cross -sectional study . Ann Allergy, Asthma 
Immunol . 2018;121(3):340 -347. https://doi.org/10.1016/j.anai.2018.07.[ADDRESS_88559] of atopic dermatitis. Ann Allergy, Asthma Immunol . 
2019;123(2):144 -151. https://doi.org/10.1016/j.anai.2019.04.020  
Silverberg JI, DeLozier A, Sun L, et al.  Psychometric properties of the itch numeric rating scale, 
skin pain numeric rating scale, and atopic dermatitis sleep scale in adult pa tients with moderate -
to-severe atopic dermatiti s. Health Qual Life Outcomes . 2021;19(1):247. 
https://doi.org/10.1186/s12955 -021-[ZIP_CODE] -8 
Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: Collegium Internationale 
Allergologicum (CIA) update 2019. Int Arch Allergy Immunol . 2019;178(3):207 -218. 
https://doi.org/10.1159/000497383  
Simpson E, Bieber T, Guttman -Yassky E, et al.  Two phase 3 trials of dupi[INVESTIGATOR_81234].  N Engl J Med . 2016;375:2335 -2348. 
https://doi.org/10.1056/nejmoa1610020  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
106 Simpson E, Eckert L, Gadkari A, et al.  Validation of the Atopic Dermatitis Control Tool 
(ADCT©) using a longitudinal survey of biologic -treated patients with atopic dermatitis. BMC 
Dermatol . 2019;19(1):15. https://doi. org/10.1186/s12895 -019-0095 -3 
Stalder J, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report 
of the European Task Force on Atopic Dermatitis.  Dermatology . 1993;186(1):23 -31. 
https://doi.org/10.1159/000247298  
Suárez -Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and 
higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin 
Immunol . 2013;132(2):361 -370. https://doi.org/10.1016/j.jaci.2013.04.[ADDRESS_88560] terminal differentiation defects and variable immune abnormalities. J Allergy Clin 
Immunol . 2011;127(4):954 -964.e1 -4. https://doi.org/10.1016/j.jaci.2010.12.1124  
Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets . 2009;8(5):398 -404. 
https://doi.org/10.2174/1871528110908050398  
Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL -4 and IL -13 in lesional 
skin of atopic dermatitis. Arch Dermatol Res . 2004;295(11):459 -464. 
https://doi.org/10.1007/s00403 -004-0455 -6 
Tracey E, Elston C, Feasel P, et al.  Erythrodermic presentation of psoriasis in a patient treated 
with dupi[INVESTIGATOR_12458] . JAAD Case Reports . 2018 ;4(7): 708-710. 
https://doi.org/10.1016/j.jdcr.2018.05.014  
Treister AD, Lio PA. Long -term off -label dupi[INVESTIGATOR_81235]: a case series. 
Pediatr Dermatol . 2019;36(1):85 -88. https://doi.org/10.1111/pde.[ADDRESS_88561] Dermatol . 2019; 139:1480 -
1489.  https://doi.org/10.1016/j.jid.2018.12.018  
Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy, 
Asthma Immunol . 2017;119(6):548 -552.e3.  https://dx.doi.org/10.1016%2Fj.anai.2017.09.076  
Van Bever HPS, Llanora G. Features of childhood atopic dermatitis. Asian  Pac J Allergy 
Immunol . 2011;29(1):15 -24.  
Varma A, Levitt J . Dupi[INVESTIGATOR_12458] -induced phenotype switching from atopic dermatitis to psoriasis . 
JAAD Case Reports . 2020; 6(3):217 -218. https://doi.org/10.1016/j.jdcr.2020.01.012  
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers . 2018;4(1):1. 
https://doi.org/10.1038/s41572 -018-0001 -z 
Weidinger S, Novak N. Atopic dermatitis. Lancet . 2016;387([ZIP_CODE]):1109 -1122. 
https://doi.org/10.1016/S0140 -6736(15)[ZIP_CODE] -X 
Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms 
in patients with atopic dermatitis. J Allergy Clin Immunol . 2016;138(2):336 -349. 
https://doi.org/10.1016/j.jaci.2016.06.010  
Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? 
J Allergy Clin Immunol . 2008;121(4):947 -954.e15. https://doi.org/10.1016/j.jaci.2007.11.004  
Approved on 27 Apr 2023 GMT
CONFIDENTIAL  J2T-MC-KGBO (a) 
107 Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapi[INVESTIGATOR_41377] -mediated inflammat ory diseases: consensus recommendations for infection reporting 
during clinical trials and postmarketing surveillance. Ann Rheum Dis . 2015;74(12):2107 -2116. 
https://doi.org/10.1136/annrheumdis -2015 -207841  
Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric 
validation and responder definition for assessin g itch in moderate -to-severe atopic dermatitis. 
Br J Dermatol . 2019 ;181(4): 761-769. https://doi.org/10.1111/bjd.[ZIP_CODE]  
Yosipovitch G, Rams A, Baldasaro J, et al.  Content Validity And Assessment Of The 
Psychometric Properties And Score Interpretation Of A Pruritus Numeric Rating Scale In 
Atopic Dermatitis. Revolutionizing Atopic Dermatitis – December, 2021.  
Zuberbier, T, Orlow SJ, Paller AS, et al. Patient perspect ives on the management of atopic 
dermatitis. J Allergy Clin Immunol . 2006;118(1):226 -232. 
https://doi.org/10.1016/j.jaci.2006.02.031  
Approved on 27 Apr 2023 GMT
Signature [CONTACT_11032]-CLIN-093432 v1.0
Signature [CONTACT_11032]-CLIN-093432 v1.0Approval
27-Apr-2023 11:25:23 GMT[PHONE_006]
Approval
27-Apr-2023 20:57:20 GMT[PHONE_006]
Approved on 27 Apr 2023 GMT
[COMPANY_003]
[COMPANY_003]